NantHealth (NHIQ) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 10, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	NantHealth, Inc.
Entity Central Index Key	1,566,469
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		108,329,668

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 73,493	$ 157,573
Accounts receivable, net	12,037	11,673
Inventories	974	1,685
Deferred implementation costs	1,121	606
Related party receivables, net	500	693
Prepaid expenses and other current assets	4,224	3,356
Current assets of discontinued operations	0	9,992
Total current assets	92,349	185,578
Property, plant, and equipment, net	19,984	20,129
Deferred implementation costs, net of current	4,374	3,201
Deferred income tax assets, net	0	84
Goodwill	114,625	114,625
Intangible assets, net	71,621	78,812
Investment in related party	160,542	207,197
Related party receivable, net of current	1,798	1,971
Other assets	1,834	2,111
Noncurrent assets of discontinued operations	0	70,683
Total assets	467,127	684,391
Current liabilities
Accounts payable	4,099	6,039
Accrued and other current liabilities	19,968	20,032
Deferred revenue	9,200	9,600
Related party payables, net	5,502	8,082
Current liabilities of discontinued operations	0	13,496
Total current liabilities	38,769	57,249
Deferred revenue, net of current	6,807	11,127
Related party liabilities	10,011	5,612
Related party promissory note	112,666	112,666
Related party convertible note, net	7,847	7,564
Convertible notes, net	73,787	70,810
Deferred income taxes, net	7,776	0
Other liabilities	719	820
Noncurrent liabilities of discontinued operations	0	6,949
Total liabilities	258,382	272,797
Stockholders' equity
Common stock, $0.0001 par value per share, 750,000,000 shares authorized; 106,963,706 and 121,250,437 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively (Including 6,976 shares of restricted stock)	11	12
Additional paid-in capital	880,801	886,334
Accumulated deficit	(671,599)	(475,273)
Accumulated other comprehensive (loss) income	(468)	521
Total stockholders' equity	208,745	411,594
Total liabilities and stockholders' equity	$ 467,127	$ 684,391

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock authorized (shares)	750,000,000	750,000,000
Common stock issued (shares)	106,963,706	121,250,437
Common stock outstanding (shares)	106,963,706	121,250,437
Unvested restricted stock
Restricted stock (units)	6,976	6,976

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Software and hardware		$ 1,162	$ 2,065	$ 4,408	$ 6,077
Software–as-a-service		15,200	14,000	44,863	41,809
Total software-related revenue		16,362	16,065	49,271	47,886
Maintenance		2,696	1,979	8,182	6,979
Sequencing and molecular analysis		1,025	77	1,985	122
Other services		1,677	2,541	4,940	7,571
Total net revenue		21,760	20,662	64,378	62,558
Cost of Revenue:
Software and hardware		443	528	596	668
Software-as-a-service		5,859	4,159	17,143	14,791
Total software-related cost of revenue		6,302	4,687	17,739	15,459
Maintenance		274	112	564	621
Sequencing and molecular analysis		1,757	570	4,807	929
Other services		1,996	2,623	5,504	9,309
Amortization of developed technologies		1,143	2,044	4,029	6,896
Total cost of revenue		11,472	10,036	32,643	33,214
Gross profit		10,288	10,626	31,735	29,344
Operating Expenses:
Selling, general and administrative		17,521	22,034	54,181	88,860
Research and development		7,749	9,960	25,051	36,519
Amortization of acquisition-related assets		1,054	1,054	3,163	3,162
Total operating expenses		26,324	33,048	82,395	128,541
Loss from operations		(16,036)	(22,422)	(50,660)	(99,197)
Interest expense, net		(4,067)	(1,415)	(12,049)	(4,760)
Other income, net		60	104	308	541
Loss from related party equity method investment including impairment loss		(2,942)	(2,604)	(46,353)	(7,893)
Loss from continuing operations before income taxes		(22,985)	(26,337)	(108,754)	(111,309)
Provision for (benefit from) income taxes		30	55	85	(19,203)
Net loss from continuing operations		(23,015)	(26,392)	(108,839)	(92,106)
Loss from discontinued operations, net of tax		(19,383)	(10,482)	(44,738)	(32,045)
Net loss		$ (42,398)	$ (36,874)	$ (153,577)	$ (124,151)
Common Stock
Continuing operations
Basic and diluted (usd per share)	[1]	$ (0.20)	$ (0.22)	$ (0.91)	$ (0.90)
Discontinued operations
Basic and diluted (usd per share)	[1]	(0.17)	(0.08)	(0.37)	(0.29)
Total net income (loss) per share
Basic and diluted (usd per share)	[1]	$ (0.37)	$ (0.30)	$ (1.28)	$ (1.19)
Weighted average shares outstanding:
Basic and diluted (shares)	[1]	115,924,122	121,245,440	119,745,231	108,359,973
Redeemable Common Stock
Continuing operations
Basic and diluted (usd per share)			$ 0
Discontinued operations
Basic and diluted (usd per share)			0
Total net income (loss) per share
Basic and diluted (usd per share)			$ 0		$ 0.74	[1]
Weighted average shares outstanding:
Basic and diluted (shares)	[1]				6,686,653
[1]	The net income (loss) per share and weighted average shares outstanding for the nine months ended September 30, 2016, have been computed to give effect to the LLC Conversion (See Note 16) that occurred on June 1, 2016, prior to the Company’s initial public offering ("IPO"). In conjunction with the LLC Conversion, (a) all of the Company’s outstanding units automatically converted into shares of common stock, based on the relative rights of the Company's pre-IPO equityholders as set forth in the Company's limited liability company agreement and (b) the Company adopted and filed a certificate of incorporation with the Secretary of State of the state of Delaware and adopted bylaws. The Company adopted and filed an amendment to its certificate of incorporation with the Secretary of State of the state of Delaware to effect a 1-for-5.5 reverse stock split of its common stock on June 1, 2016.The net loss per share for the common stock for the nine months ended September 30, 2016 reflects $4,958 in accretion value allocated to the redeemable common stock. The redeemable common stock contained a put right, which expired unexercised on June 20, 2016. As a result of and as of that date, the shares were no longer redeemable and were included in common stock. See Note 19 for the calculation of net loss per share for common stock and redeemable common stock for the nine months ended September 30, 2016.

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations - Footnote $ in Thousands	Jun. 01, 2016	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2015USD ($)
Income Statement [Abstract]
Reverse stock split, conversion ratio	0.1818
Accretion to redemption value		$ 0	$ 0	$ 4,958	$ 16,042

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net loss		$ (42,398)	$ (36,874)	$ (153,577)	$ (124,151)
Share in related party equity investment - other comprehensive loss		(302)	0	(302)	0
Amounts reclassified from accumulated other comprehensive income	[1]	(977)	0	(977)	0
Other comprehensive income from foreign currency translation gain		210	254	290	647
Comprehensive loss		$ (43,467)	$ (36,620)	$ (154,566)	$ (123,504)
[1]	See Note 3, "Discontinued Operations," for a discussion of this reclass of foreign currency translation adjustment.

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (153,577)	$ (124,151)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	23,288	22,990
Amortization of debt discounts and deferred financing offering cost	3,260	0
Change in fair value of derivatives liability	(245)	0
Unrealized changes in fair value of marketable securities	0	(49)
Realized changes in fair value of marketable securities	0	49
Stock-based compensation	(4,076)	48,982
Deferred income taxes, net	6,988	(18,752)
Provision for bad debt expense	155	522
Inventory provision	692	479
Loss from related party equity method investment including impairment loss	46,353	7,893
Loss on sale of business and dissolution of a business component	10,673	0
Other non-cash expense	0	144
Changes in operating assets and liabilities, net of business combinations and divestitures:
Accounts receivable, net	(500)	8,950
Inventories	61	(135)
Related party receivables, net	637	(324)
Prepaid expenses and other current assets	(494)	4,883
Deferred implementation costs	(1,951)	(6,695)
Accounts payable	(966)	(4,315)
Accrued and other current liabilities	(4,127)	1,729
Deferred revenue	(2,053)	3,304
Related party payables, net	2,108	2,278
Other assets and liabilities	305	71
Net cash used in operating activities	(73,469)	(52,147)
Cash flows from investing activities:
Purchase of property and equipment including internal use software	(12,556)	(12,701)
Proceeds from sale of business, net of cash disposed	1,721	0
Purchases of marketable securities	0	(31)
Proceeds from sales of marketable securities	0	1,275
Proceeds from sales of property and equipment	0	138
Acquisitions of businesses, net of cash acquired	0	(79,423)
Deferred consideration for acquisition	0	1,949
Net cash used in investing activities	(10,835)	(88,793)
Cash flows from financing activities:
Deemed capital contribution from Chairman and CEO	0	3,420	$ 10,000
Payment of short-term notes payable	0	(23,324)
Proceeds from related party promissory note	0	152,666
Proceeds from initial public offering, net of offering costs	0	83,566
Tax payments related to stock issued, net of stock withheld, for vested phantom units	(2,740)	(5,822)
Net cash provided by (used in) financing activities	(2,740)	210,506
Effect of exchange rate changes on cash and cash equivalents	184	246
Net increase (decrease) in cash and cash equivalents	(86,860)	69,812
Cash and cash equivalents, beginning of period (including cash of discontinued operations)			160,353	$ 5,989
Cash and cash equivalents, end of period	73,493	75,801	$ 157,573
Supplemental disclosure of cash flow information:
Interest paid	(2,836)	(9)
Interest received	62	108
Non-cash transactions:
Purchase of property and equipment (including internal use software)	811	967
Non cash consideration (common stock) from sale of Business (see Note 3) and subsequent retirement of stock	42,750	0
NaviNet escrow receivable	0	1,678
Accretion to redemption value of Series F units / redeemable common stock	0	4,958		$ 16,042
Conversion of related party promissory note and interest payable to common stock	0	40,590
Reclassification of redeemable common stock to common stock (former Series F units)	$ 0	$ 171,000

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Nature of Business Nant Health, LLC was formed on July 7, 2010, as a Delaware limited liability company. On June 1, 2016, Nant Health, LLC converted into a Delaware corporation (the “LLC Conversion”) and changed its name to NantHealth, Inc. (“NantHealth”). NantHealth, together with its subsidiaries (the “Company”), is a healthcare IT company converging science and technology. The Company works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The Company’s technology empowers physicians, patients, payers and researchers to transcend genomics into the world of proteomics. NantHealth is a majority-owned subsidiary of NantWorks, LLC (“NantWorks”), which is a subsidiary of California Capital Equity, LLC (“Cal Cap”). The three companies were founded by and are led by Dr. Patrick Soon-Shiong. On August 25, 2017, the Company sold substantially all of the assets of the Company’s provider/patient engagement solutions business. The sale will enable the Company to focus on its core competencies of genomic sequencing, clinical decision support, connected care and payer engagement. As of September 30, 2017 , the Company conducted the majority of its operations in the United States, Canada, the United Kingdom, and Singapore. LLC Conversion and Initial Public Offering On June 1, 2016, immediately prior to the pricing of its initial public offering (“IPO”) and in conjunction with the LLC Conversion, all outstanding units of Nant Health, LLC were automatically converted into shares of the Company’s common stock. Immediately following the LLC Conversion, the Company effected a 1 -for- 5.5 reverse stock split of its common stock. All share and per share amounts in the Condensed Consolidated Financial Statements and notes thereto have been retroactively adjusted, where necessary, to give effect to this reverse stock split. On June 7, 2016, the Company completed its IPO, whereby it sold 6,500,000 shares of common stock at a public offering price of $14.00 per share. Additionally, on June 9, 2016, the underwriters partially exercised their over allotment option to purchase an additional 400,000 shares of common stock at $14.00 per share. The Company received a total of $83,566 in proceeds from its IPO, after deducting underwriting discounts and commissions and offering costs of $13,034 . The offering was registered under the Securities Act of 1933, as amended, on a registration statement on Form S-1 (Registration No. 333-211196), as amended. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of NantHealth and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These interim Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). These Financial Statements have been prepared on the same basis as the audited Consolidated Financial Statements for the fiscal year ended December 31, 2016 and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company's financial position and results of operation. The results of operations of the entities disposed of are included in the unaudited condensed consolidated financial statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. Certain reclassifications have been made to prior period amounts to conform to the current year presentation. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2016 has been derived from the audited Consolidated Financial Statements at that date but does not include all of the disclosures required by GAAP. Assets and liabilities of the discontinued operations are presented separately in the asset and liability sections of the prior period balance sheet. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year. The Company believes its existing cash, cash equivalents and ability to borrow from affiliated entities under existing facilities will be sufficient to fund operations through at least the next 12 months. If these sources are insufficient to satisfy the Company's liquidity requirements, it may seek to sell additional equity, through one or more follow-on public offerings or in separate financings, or sell additional debt securities or obtain a credit facility. Further, because of the risk and uncertainties associated with the commercialization of the Company's existing products as well as products in development, the Company may need additional funds to meet its needs sooner than planned. To date, the Company's primary sources of capital were private placement of membership interests prior to its IPO, debt financing agreements, including the promissory note with NantCapital, LLC (“NantCapital”), convertible notes, and its IPO. Principles of Consolidation The accompanying Condensed Consolidated Financial Statements include the financial statements of the Company and its wholly owned subsidiaries. All intercompany balances and transactions with the Company’s subsidiaries have been eliminated.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies There have been no significant changes to the accounting policies as disclosed in the Company's Annual Report on Form 10-K. The accounting policies are described in the Company’s Annual Report on Form 10-K. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates. Segment Reporting The chief operating decision maker for the Company is its Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a Condensed Consolidated basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, or plans for levels or components below the Condensed Consolidated unit level. Accordingly, management has determined that the Company operates in one reportable segment. Recent Accounting Pronouncements Revenue from Contracts with Customers The new FASB Topic 606 standards commencing with Accounting Standard Update ("ASU") No. 2014-09 ("Topic 606"), Revenue from Contracts with Customers replace existing revenue recognition rules including industry-specific guidance. Topic 606 outlines a five-step process for revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards, and also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Major provisions include determining which goods and services are distinct and require separate accounting (performance obligations), how variable consideration (which may include change orders and claims) is recognized, whether revenue should be recognized at a point in time or over time and ensuring the time value of money is considered in the transaction price. Revenue is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for goods or services. The provisions of Topic 606 will become effective for annual reporting periods beginning after December 15, 2017. The FASB allows two adoption methods under Topic 606 standards. Under one method, a company will apply the rules to contracts in all reporting periods presented, subject to certain allowable exceptions. Under the other method, a company would apply the rules to all contracts existing as of January 1, 2018, recognizing in the opening balance of retained earnings an adjustment for the cumulative effect of the change and providing additional disclosures comparing results to previous rules. As permitted under the standard, the Company plans to adopt ASU 2014-09 in the first quarter of 2018 using the modified retrospective approach and to recognize the cumulative effect of existing contracts in the opening balance of retained earnings on the effective date of January 1, 2018. The Company continues to assess the impact of the new revenue standard on the current business processes, systems and controls. Upon initial evaluation, the Company expects that one significant impact will likely be to its software arrangements due to the requirement to estimate the selling price for deliverables. Under current revenue accounting guidance, if VSOE does not exist for license and implementation fees, the Company recognizes those revenues over the post contract support period. Also, the principal versus agent analysis under Topic 606 focuses on whether the entity controls each specified good or service in an arrangement and the company is currently evaluating whether the guidance will have an impact on how the Company reports its sequencing and molecular analysis revenue. The Company is also assessing the impact of capitalizing costs associated with obtaining customer contracts, specifically commission and incentive payments. Currently, these payments are expensed in the period they are incurred. Under the updated guidance, certain of these payments may be deferred on the Company's Condensed Consolidated Balance Sheets and amortized over the expected life of the customer contract. Other accounting pronouncements In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): C larifying the Definition of a Business . This standard clarifies the definition of a business and provides a screen to determine if a set of inputs, processes and outputs is a business. The screen requires that when substantially all of the fair value of gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the assets acquired would not be a business. Under the new guidance, in order to be considered a business, an acquisition must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output. In addition, the standard narrows the definition of the term “output” so that it is consistent with how it is described in Topic 606 standards. This standard will be effective for annual periods beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently evaluating the impact this guidance may have on its Condensed Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) to simplify the accounting for goodwill impairment. This guidance, among other things, removes step 2 of the goodwill impairment test thus eliminating the need to determine the fair value of individual assets and liabilities of the reporting unit. Upon adoption of this ASU, goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This may result in more or less impairment being recognized than under current guidance. This update will become effective for the Corporation’s annual and interim goodwill impairment tests beginning in the first quarter of 2020, and early adoption is permitted. The Company is still evaluating the impact of this standard update. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" (“ASU 2016-02”). The update is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for interim and annual reporting periods beginning with the year ending December 31, 2019. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its Condensed Consolidated Financial Statements. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission ("SEC") did not have, or are not believed by management to have, a material impact on the Company's present or future Condensed Consolidated Financial Statements.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations Sale to Allscripts On August 3, 2017, the Company entered into an asset purchase agreement (the “APA”) with Allscripts Healthcare Solutions, Inc. (“Allscripts”), pursuant to which the Company agreed to sell to Allscripts substantially all of the assets of the Company’s provider/patient engagement solutions business, including the Company’s FusionFX solution and components of its NantOS software connectivity solutions (the “Business”). On August 25, 2017, the Company and Allscripts completed the sale of the Business (the "Disposition") pursuant to the APA. Allscripts conveyed to the Company 15,000,000 shares of Company's common stock at par value of $0.0001 per share that were previously owned by Allscripts as consideration for the acquired Business upon Disposition. Allscripts paid the Company $1,742 of cash consideration as an estimated working capital payment, and such amount was subject to adjustment based upon the final amount of working capital as of the closing date. The Company is also responsible for paying Allscripts for fulfilling certain customer service obligations of the Business post-closing, and the Company may be entitled to receive from Allscripts up to an additional $1,110 cash consideration for the Business if Allscripts receives such amounts from certain customers after the Disposition. Concurrent with the closing of the Disposition and as contemplated by the APA, (a) the Company and Allscripts modified the amended and restated mutual license and reseller agreement dated June 26, 2015, as amended, such that, among other things, the Company committed to deliver a minimum dollar amount of total bookings over a ten year period; (b) the Company and Allscripts each licensed certain intellectual property to the other party pursuant to a cross license agreement; (c) the Company agreed to provide certain transition services to Allscripts pursuant to a transition services agreement; and (d) the Company licensed certain software and agreed to sell certain hardware to Allscripts pursuant to a software license and supply agreement. The total loss on sale to Allscripts consisted of the following: Cash received as consideration $ 1,742 Estimated costs to be incurred by the Company to fulfill certain customer service obligations of (887 ) Fair value of common stock 42,750 Net consideration received 43,605 Less: Carrying value of net assets sold (55,255 ) Plus: Reclassification of cumulative translation adjustments of foreign subsidiaries 117 Loss from sale of Business $ (11,533 ) The sale of the Business qualified as a discontinued operations because it comprised operations and cash flows that could be distinguished, operationally and for financial reporting purposes, from the rest of the Company. The disposal of the Business represented a strategic shift in the Company’s operations as the sale enables the Company to focus on genomic sequencing, clinical decision support, connected care and payer engagement. The carrying amounts of the major classes of assets and liabilities of the Company's discontinued operations as of December 31, 2016 are as follows: December 31, Cash and cash equivalents $ 2,780 Accounts receivable, net 2,055 Inventories 532 Deferred implementation costs 2,730 Related party receivables, net 206 Prepaid expenses and other current assets 1,689 Current assets of discontinued operations 9,992 Property, plant, and equipment, net 9,010 Deferred implementation costs, net of current 4,709 Goodwill 16,444 Intangible assets, net 40,314 Other assets 206 Total assets of discontinued operations $ 80,675 Accounts payable $ 681 Accrued and other current liabilities 5,199 Deferred revenue 7,616 Current liabilities of discontinued operations 13,496 Deferred revenue, net of current 6,111 Deferred income tax liabilities, net of current 838 Total liabilities of discontinued operations $ 20,445 The operating results of the Company's discontinued operations are as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Major line items constituting income from discontinued operations Net revenue $ 1,498 $ 4,695 $ 7,619 $ 13,740 Cost of revenue 1,787 7,200 16,318 19,300 Selling, general and administrative 1,515 2,681 8,675 10,476 Research and development (372 ) 3,895 7,571 12,352 Amortization of software license and acquisition-related assets 458 760 1,978 2,280 Other (income) expense 216 440 134 527 Loss from sale of Business 11,533 — 11,533 — Gain from dissolution of a business component (860 ) — (860 ) — Loss from discontinued operations, before income taxes (12,779 ) (10,281 ) (37,730 ) (31,195 ) Provision for income taxes 6,604 201 7,008 850 Loss from discontinued operations, net of income taxes $ (19,383 ) $ (10,482 ) $ (44,738 ) $ (32,045 ) Cumulative translation adjustment gains or losses of foreign subsidiaries related to divested Business are reclassified into income once the liquidation of the respective foreign subsidiaries is substantially complete. At the completion of the sale of the Business, the Company reclassified $ 117 of cumulative translation adjustment gains from accumulated comprehensive loss to the Company's loss from sale of Business. The significant operating and investing cash and non-cash items of the discontinued operations included in the unaudited condensed consolidated statements of cash flows for the nine months ended September 30, 2017 and 2016 were as follows: Nine Months Ended 2017 2016 Depreciation and amortization from discontinued operations $ 8,829 $ 8,645 Loss from sale of Business 11,533 — Proceeds from sale of Business 1,721 — Capital expenditures 4,668 144 Dissolution of Net.Orange Ltd On August 29, 2017, the Company dissolved its wholly-owned U.K. subsidiary, Net.Orange Ltd. The Company reclassified $ 860 of cumulative translation adjustment gains from accumulated comprehensive loss to the Company's results of discontinued operations.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Business Combinations	Business Combinations NaviNet, Inc. Acquisition in 2016 On November 30, 2015, NantHealth entered into a definitive agreement with 3BE Holdings, LLC (“3BE”) to acquire 100% of the outstanding equity interest of NaviNet, Inc. (“NaviNet”) in exchange for $83,529 in cash, subject to working capital adjustments, 15,513,726 newly issued Series H units with a fair value of $52,500 and contingent arrangements or earnouts of up to $12,250 , which was effective on January 1, 2016 (See Note 7). The contingent arrangements or earnouts require the Company to pay up to a total of $12,250 to certain of NaviNet’s former shareholders if NaviNet’s revenues to those former shareholders exceed certain thresholds during the years ended December 31, 2016 and 2017. These contingent amounts or earnouts have been excluded from the purchase price consideration and are accounted for as sales incentives as certain predefined targets are met and are reflected as contra revenue. The cash portion of the acquisition was financed through a promissory note with NantCapital, an affiliate of the Company (See Note 20). In June 2016, the Company paid an additional $455 to 3BE as a working capital adjustment and accounted for the payment as an increase to the purchase price of NaviNet. In December 2016, and in accordance with the definitive agreements, the Company received $2,409 out of the escrow account for the settlement of the final net working capital adjustment. The following table summarizes the total purchase consideration for the acquisition: Amounts Cash paid to 3BE at closing $ 74,823 Cash paid to option holders after closing 2,580 Cash paid to escrow account 6,126 Working capital settlement payment 455 Fair value of Series H units 52,500 Total consideration $ 136,484 The total consideration was allocated to the net assets acquired based upon their estimated fair values: Amounts Cash and restricted cash $ 4,804 Accounts receivable, net 10,693 Property, plant and equipment 5,044 Other assets and liabilities, net 4,561 Accounts payable (4,585 ) Accrued and other current liabilities (3,674 ) Deferred revenue (2,603 ) Deferred tax liability (15,508 ) Assumed indebtedness (23,324 ) Trade names 3,000 Developed technology 32,000 Customer relationships 52,000 Goodwill 74,076 Total fair value of net assets acquired $ 136,484 The estimated life of the acquired trade names is four years, the estimated life of customer relationships is fifteen years and the estimated life of the developed technology is seven years, with these intangibles amortized on a straight-line basis. The excess of the purchase price over the net tangible and intangible assets of $74,076 was recorded as goodwill, and considered non-deductible for income tax purpose. At the closing of the acquisition, the Company repaid all $23,324 of assumed indebtedness presented in the table above. During the year ended December 31, 2016, the Company recognized $300 in measurement period adjustments, which reduced goodwill. The measurement period adjustments included a $2,909 increase to goodwill related to a decrease in property and equipment; a $697 decrease to goodwill related to an increase in research and development grant receivable; a $955 decrease to goodwill related to a decrease in deferred revenue; a $209 increase to goodwill related to a deferred tax liability increase due to various allocation adjustments; a $455 increase to goodwill for working capital adjustments; a $188 increase to goodwill related to an accrued sales tax liability increase; and, a $2,409 decrease to goodwill, representing the Company’s right to be reimbursed from 3BE for severance benefits if their employment is terminated by the Company without cause or by the employee for good reason within 12 months after the closing date, which was settled through the escrow account in December 2016.

Accounts Receivable, net

Accounts Receivable, net	9 Months Ended
	Sep. 30, 2017
Receivables [Abstract]
Accounts Receivable, net	Accounts Receivable, net Accounts receivable, net excludes amounts related to post contract client support (“PCS”) and other services that were billed but not yet delivered at each period end. These undelivered services are also excluded from the deferred revenue balances on the accompanying Condensed Consolidated Balance Sheets. The amount of outstanding and unpaid invoices excluded from both the accounts receivable and deferred revenue balances as of September 30, 2017 and December 31, 2016 was $5,676 and $1,900 , respectively. Accounts receivable are included on the Condensed Consolidated Balance Sheets, net of the allowance for doubtful accounts. The allowance for doubtful accounts at September 30, 2017 and December 31, 2016 was $148 and $70 , respectively.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Finished goods $ 974 $ 1,308 Raw materials — 377 Inventories $ 974 $ 1,685

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities	9 Months Ended
	Sep. 30, 2017
Other Current Assets And Other Current Liabilities [Abstract]
Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities	Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Prepaid expenses and other current assets as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Prepaid expenses $ 3,734 $ 3,083 Restricted cash 350 100 Other current assets 140 173 Prepaid expenses and other current assets $ 4,224 $ 3,356 Accrued and other current liabilities of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Payroll and related costs $ 8,109 $ 9,821 NaviNet acquisition accrued earnout (See Note 4) 4,736 2,675 Other accrued and other current liabilities 7,123 7,536 Accrued and other current liabilities $ 19,968 $ 20,032
Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities	Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Prepaid expenses and other current assets as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Prepaid expenses $ 3,734 $ 3,083 Restricted cash 350 100 Other current assets 140 173 Prepaid expenses and other current assets $ 4,224 $ 3,356 Accrued and other current liabilities of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Payroll and related costs $ 8,109 $ 9,821 NaviNet acquisition accrued earnout (See Note 4) 4,736 2,675 Other accrued and other current liabilities 7,123 7,536 Accrued and other current liabilities $ 19,968 $ 20,032

Property, Plant and Equipment,

Property, Plant and Equipment, net	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Property, Plant and Equipment, net Property, plant and equipment, net as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Computer equipment and software $ 13,956 $ 13,391 Furniture and equipment 3,198 3,169 Leasehold and building improvements 4,230 3,921 Internal use software 15,853 10,371 Construction in progress 1,444 1,090 38,681 31,942 Less: accumulated depreciation and amortization (18,697 ) (11,813 ) Property, plant and equipment, net $ 19,984 $ 20,129 Depreciation and amortization expense from continuing and discontinued operations was $3,197 for the three months ended September 30, 2017 , of which $1,546 related to internal use software costs. Depreciation and amortization expense from continuing and discontinued operations was $1,995 for the three months ended September 30, 2016 , of which $410 related to internal use software costs. Depreciation and amortization expense from continuing and discontinued operations was $9,793 for the nine months ended September 30, 2017 , of which $4,402 related to internal use software costs. Depreciation and amortization expense from continuing and discontinued operations was $5,664 for the nine months ended September 30, 2016 , of which $686 related to internal use software costs. Amounts capitalized to internal use software for the three months ended September 30, 2017 and 2016 were $976 and $4,018 , respectively. Amounts capitalized to internal use software for the nine months ended September 30, 2017 and 2016 were $5,482 and $6,271 , respectively.

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net The Company’s definite-lived intangible assets as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Customer relationships $ 52,400 $ 52,400 Developed technologies 61,130 61,130 Trade name 3,000 3,000 116,530 116,530 Less: accumulated amortization (44,909 ) (37,718 ) Intangible assets, net $ 71,621 $ 78,812 Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or the pattern in which economic benefits are consumed, if reliably determinable. The Company reviews its definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization expense from continuing operations and discontinued operations was $3,656 and $5,520 for the three months ended September 30, 2017 and 2016 , respectively. Amortization expense from continuing and discontinued operations was $13,495 and $17,326 for the nine months ended September 30, 2017 and 2016 , respectively. During the nine months ended September 30, 2016 , the Company recorded $87,000 of definite-lived intangible assets related to the acquisition of NaviNet (See Note 4). These intangibles are amortized over a period of four to fifteen years. The estimated future amortization expense over the next five years and thereafter for the intangible assets that exist as of September 30, 2017 is as follows: Amounts Remainder of 2017 $ 2,197 2018 8,788 2019 8,788 2020 8,038 2021 8,038 Thereafter 35,772 Total future intangible amortization expense $ 71,621

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Goodwill as of September 30, 2017 and December 31, 2016 was $114,625 , net of goodwill allocated to discontinued operations of $16,444 . The value of goodwill associated with the discontinued operations was based on the relative fair value of the Business disposed to the total reporting unit as of August 25, 2017 (See Note 3). On January 1, 2016 the Company added $74,076 of goodwill related to the acquisition of NaviNet (See Note 4). Measurement period adjustments during the three months ended September 30, 2016 resulted in a reduction of $697 to goodwill, including $697 reduction of goodwill related to the NaviNet acquisition (See Note 4). Measurement period adjustments during the nine months ended September 30, 2016 resulted in an increase of $1,635 to goodwill, including an increase of $1,361 related to the NaviNet acquisition, and an increase of $274 related to the asset acquisition of Healthcare Solutions from Harris Corporation from 2015. Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized but is tested for impairment annually as of October 1 or between annual tests when an impairment indicator exists.

Investments

Investments	9 Months Ended
	Sep. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments Equity method investment Investment in NantOmics In 2015 the Company purchased a total of 169,074,539 Series A-2 units of NantOmics, LLC (“NantOmics”), a related party of the Company, for an aggregate purchase price of $250,774 . The Series A-2 units do not have any voting rights and represent approximately 14.28% of NantOmics’ issued and outstanding membership interests. NantOmics is majority owned by NantWorks and delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. The Company applies the equity method to account for its investment in NantOmics as the interest in the equity is similar to a partnership interest. Further, the Company has the ability to exert significant influence over the operating and financial policies of the entity since NantWorks controls both NantHealth and NantOmics. The difference between the carrying amount of the investment in NantOmics and the Company’s underlying equity in NantOmics’ net assets relate to both definite and indefinite-lived intangible assets. The Company attributed $28,195 and $14,382 of these differences to NantOmics’ developed technologies and its reseller agreement with the Company, respectively, prior to the application of developed technology intangibles included in NantOmics net assets, and the remaining basis differences were attributed to goodwill. The Company amortizes the basis differences related to the definite-lived intangible assets over the assets’ estimated useful lives and records these amounts as a reduction in the carrying amount of its investment and an increase in its equity method loss. The investment in related party is assessed for possible impairment when events indicate that the fair value of the investment may be below the carrying value. When such a condition is deemed to be other than temporary, the carrying value of the investment is written down to its fair value, and the amount of the write-down is included in net loss. In making the determination as to whether a decline is other than temporary, the Company considers such factors as the duration and extent of the decline, the investee’s financial performance, and the Company's ability and intention to retain the investment for a period that will be sufficient to allow for any anticipated recovery in the investment’s market value. The new cost basis of the investment is not changed for subsequent recoveries in fair value. The fair value of the Company's equity method investment is determined using the income approach. The income approach utilizes a discounted cash flow model incorporating management’s expectations for future revenue, operating expenses, and earnings before interest, taxes, depreciation and amortization, capital expenditures and an anticipated tax rate. The related cash flow forecasts are discounted using an estimated weighted-average cost of capital at the date of valuation. Differences between the carrying value of an equity investment and its underlying equity in the net assets of the related party are assigned to the extent practicable to specific assets and liabilities based on our analysis of the various factors giving rise to the difference. When appropriate, the Company's share of the related party’s reported earnings is adjusted quarterly to reflect the difference between these allocated values and the related party’s historical book values. At June 30, 2017 and at December 31, 2016, the Company determined that other than temporary impairments of $35,991 and $29,816 , respectively, in the value of the investment in NantOmics had occurred, predominantly attributed to declines in the value of goodwill. The declines in the fair value were primarily caused by delays in the Company’s GPS revenue growth and changes in the risk profile of the financial projections for NantOmics. The Company based its financial projections on information that the Company believed were reasonable; however, actual results may differ materially from those projections. The other than temporary impairments were based on judgments and estimates that were forward looking in nature and it is reasonably possible that the estimate of the impairments of the equity method investment in NantOmics will change in the near term due to the following: actual NantOmics cash distribution is materially lower than expected, significant adverse changes in NantOmics's operating environment, increase in the discount rate, and changes in other key assumptions. Risks and uncertainties are related to assumptions regarding future financial performance, commercial acceptance of product and service offerings, risk of reimbursement for the Company’s sequencing and molecular analysis solution, developments in the healthcare and molecular diagnostics industry, NantOmics' ability to integrate its business acquisitions, regulatory risks, and other general business risks including unanticipated adverse changes in NantOmics' operating environment. The Company reports its share of NantOmics’ income or loss and the amortization of basis differences using a one quarter lag. For the three months ended September 30, 2017 and 2016 , the Company recognized equity losses of $2,942 and $2,604 , respectively. For the nine months ended September 30, 2017 and 2016 , the Company recognized equity losses of $46,353 and $7,893 , respectively. The Company used the following summarized financial information for NantOmics for the nine months ended June 30, 2017 and 2016 , respectively, to record its equity method losses for the nine months ended September 30, 2017 and 2016 : Trailing Nine Months Ended June 30, 2017 2016 Sales $ 5,294 $ 2,936 Gross loss (4,330 ) (3,113 ) Loss from operations (33,262 ) (25,693 ) Net loss (41,420 ) (21,841 ) Net loss attributable to NantOmics (39,088 ) (20,273 ) Cost method Investment Investment in IOBS On June 16, 2015, the Company invested $1,750 in Innovative Oncology Business Solutions, Inc. (“IOBS”) in exchange for 1,750,000 shares of IOBS’ Series A preferred stock. IOBS offers community oncology practices an alternative medical home model for oncology patients that improves health outcomes, enhances patient care experiences and significantly reduces costs of care. The shares of preferred stock represent 35.0% of the outstanding equity of IOBS on an as-converted basis. The Company applied the cost method to account for its investment because the preferred stock is not considered in-substance common stock, is not considered a debt instrument as the Company cannot unilaterally demand redemption of the preferred stock and the preferred stock does not have a readily determinable fair value. As of September 30, 2017 and December 31, 2016 , IOBS was considered a variable interest entity. The Company is not the primary beneficiary of IOBS because it only has the right to elect two of five directors. All major decisions of IOBS require the majority vote by the members of the board of directors, including decisions made to manage the business including hiring and firing of officers and other critical management functions. Therefore, the Company does not consolidate IOBS. The Company’s maximum exposure to loss as a result of its involvement with IOBS is approximately $1,750 , which is primarily composed of the original cost of the investment in IOBS’ Series A preferred stock. No other arrangements exist that could require the Company to provide additional financial support or otherwise expose the Company to a loss.

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Convertible Notes	Convertible Notes In December 2016, the Company entered into the Purchase Agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several initial purchasers named therein (collectively, the “Initial Purchasers”), to issue and sell $90,000 in aggregate principal amount of its 5.50% senior convertible notes due 2021 ("Convertible Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons pursuant to Regulation S under the Securities Act. In December 2016, the Company entered into a purchase agreement (the “Cambridge Purchase Agreement”) with Cambridge Equities, L.P., an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Chairman and Chief Executive Officer (“Cambridge”), to issue and sell $10,000 in aggregate principal amount of the Convertible Notes in a private placement pursuant to an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act. In December 2016, pursuant to the exercise of the overallotment by the Initial Purchasers, the Company issued an additional $7,000 principal amount of the Convertible Notes. The total net proceeds from this offering were approximately $102,714 , $9,917 from Cambridge and $92,797 from the Initial Purchasers, after deducting of Initial Purchasers’ discount and debt issuance costs of $4,286 in connection with the Convertible Notes offering. On December 21, 2016, the Company entered into an Indenture, relating to the issuance of the Convertible Notes (the “Indenture”), by and between the Company and U.S. Bank National Association, as trustee (the “Trustee”). The interest rates are fixed at 5.50% per year, payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2021, unless earlier repurchased by the Company or converted pursuant to their terms. In connection with the offering of the Convertible Notes, on December 15, 2016, the Company entered into a Second Amended and Restated Promissory Note which amended and restated the Amended and Restated Promissory Note, dated May 9, 2016, between the Company and NantCapital, to, among other things, extend the maturity date of the promissory note to June 30, 2022 and to subordinate such promissory note in right of payment to the Convertible Notes (See Note 20). The initial conversion rate of the Convertible Notes is 82.3893 shares of common stock per $1 principal amount of Convertible Notes (which is equivalent to an initial conversion price of approximately $12.14 per share). Prior to the close of business on the business day immediately preceding September 15, 2021, the Convertible Notes will be convertible only under the following circumstances: (1) during any calendar quarter commencing after March 31, 2017 (and only during such calendar quarter), if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding calendar quarter, the last reported sale price of the Company’s common stock on such trading day is greater than or equal to 120% of the conversion price on such trading day; (2) during the five -business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1 principal amount of the Convertible Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on such trading day; or (3) upon the occurrence of specified corporate transactions as described in the Indenture agreement. Upon conversion, the Convertible Notes will be settled in cash, shares of the Company’s common stock or any combination thereof at the Company’s option. Upon the occurrence of a fundamental change (as defined in the Indenture), holders may require the Company to purchase all or a portion of the Convertible Notes in principal amounts of $1 or an integral multiple thereof, for cash at a price equal to 100% of the principal amount of the Convertible Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date. The conversion rate will be subject to adjustment upon the occurrence of certain specified events. On or after the date that is one year after the last date of original issuance of the Convertible Notes, if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending within the five trading days immediately preceding a conversion date is greater than or equal to 120% of the conversion price on each applicable trading day, the Company will make an interest make-whole payment to a converting holder (other than a conversion in connection with a make-whole fundamental change in which the conversion rate is adjusted) equal to the sum of the present values of the scheduled payments of interest that would have been made on the Convertible Notes to be converted had such Convertible Notes remained outstanding from the conversion date through the earlier of (i) the date that is three years after the conversion date and (ii) the maturity date if the Convertible Notes had not been so converted. The present values of the remaining interest payments will be computed using a discount rate equal to 2.0% . The Company may pay any interest make-whole payment either in cash or in shares of its common stock, at the Company’s election as described in the Indenture. The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) by recording the liability and equity components of the convertible debt separately. The liability component is computed based on the fair value of a similar liability that does not include the conversion option. The liability component includes both the value of the embedded interest make-whole derivative and the carrying value of the Convertible Notes. The equity component is computed based on the total debt proceeds less the fair value of the liability component. The equity component is also recorded as debt discount and amortized as interest expense over the expected term of the Convertible Notes. The liability component of the Convertible Notes on the date of issuance was computed as $83,079 , consisting of the value of the embedded interest make-whole derivative of $1,499 and the carrying value of the Convertible Notes of $81,580 . Accordingly, the equity component on the date of issuance was $23,921 . If the debt will be considered current at the balance sheet date, the liability component of the convertible notes will be classified as current liabilities and presented in current portion of convertible notes debt and the equity component of the convertible debt will be considered a redeemable security and presented as redeemable equity on the Company's Condensed Consolidated Balance Sheet. Offering costs of $4,286 related to the issuance of the Convertible Notes are allocated to the liability and equity components in proportion to the allocation of the proceeds and accounted for as deferred financing offering costs and equity issuance costs, respectively. Approximately $972 of this amount was allocated to equity and the remaining $3,314 were capitalized as deferred financing offering costs. The debt discounts and deferred financing offering costs on the Convertible Notes are being amortized to interest expense over the contractual terms of the Convertible Notes, using the effective interest method at an effective interest rate of 12.82% . As of September 30, 2017 , the remaining life of the Convertible Notes is approximately 51 months . The following table summarizes how the issuance of the Convertible Notes is reflected in the Company's Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016 . Related party Others Total Balance as of September 30, 2017 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (2,153 ) (23,213 ) (25,366 ) Net carrying amount $ 7,847 $ 73,787 $ 81,634 Balance as of December 31, 2016 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (2,436 ) (26,190 ) (28,626 ) Net carrying amount $ 7,564 $ 70,810 $ 78,374 The following table sets forth the Company's interest expense recognized in the Company's Condensed Consolidated Statements of Operations: Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Related party Others Total Related party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 $ 412 $ 4,001 $ 4,413 Amortization of debt discounts 94 897 991 275 2,608 2,883 Amortization of deferred financing offering costs 3 127 130 8 369 377 Total convertible notes interest expense $ 234 $ 2,358 $ 2,592 $ 695 $ 6,978 $ 7,673

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, 2017 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets - Cash equivalents $ 64,279 $ 64,279 $ — $ — Liabilities - Interest make-whole derivative 26 — — 26 December 31, 2016 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets - Cash equivalents $ 146,287 $ 146,287 $ — $ — Liabilities - Interest make-whole derivative 271 — — 271 The Company’s intangible assets and goodwill are initially measured at fair value and any subsequent adjustment to the initial fair value occurs only if an impairment charge is recognized. The fair values of the Company’s marketable securities and cash equivalents (consisting of mainly money market accounts) are based on quoted market prices in active markets with no valuation adjustment. Level 3 Inputs In December 2016, the Company issued $107,000 in aggregate principal amount of Convertible Notes due December 15, 2021, of which $10,000 issued to a related party (See Note 12). The Convertible Notes include an interest make-whole feature whereby if a noteholder converts any of the Convertible Notes one year after the last date of original issuance of the Convertible Notes, they are entitled, in addition to the other consideration payable or deliverable in connection with such conversion, to an interest make-whole payment equal to the sum of the present values of the scheduled payments, computed using a discount rate equal to 2.0% , of interest that would have been made on the Convertible Notes to be converted had such Convertible Notes remained outstanding from the conversion date through the earlier of (i) the date that is three years after the conversion date and (ii) the maturity date if the Convertible Notes had not been so converted. The Company may pay any interest make-whole payment either in cash or in shares of its common stock, at the Company’s election as described in the Indenture. The Company has determined that this feature is an embedded derivative and have recognized the fair value of this derivative as a liability in the Company's Condensed Consolidated Balance Sheets, with subsequent changes to fair value recorded through earnings at each reporting period as part of other income, net on the Company's Condensed Consolidated Statements of Operations as change in fair value of derivative liability. The following tables set forth a summary of changes in the fair value of Level 3 liabilities for the three and nine months ended September 30, 2017 : June 30, 2017 Additions Change in fair value September 30, 2017 Interest make-whole derivative liability: Related party $ 3 $ — $ (1 ) $ 2 Others 29 — (5 ) 24 $ 32 $ — $ (6 ) $ 26 December 31, 2016 Additions Change in fair value September 30, 2017 Interest make-whole derivative liability: Related party $ 25 $ — $ (23 ) $ 2 Others 246 — (222 ) 24 $ 271 $ — $ (245 ) $ 26 As of September 30, 2017 and December 31, 2016 , the fair value and carrying value of the Company's Convertible Notes were: Fair value Carrying value Face value 5.5% convertible senior notes due December 15, 2021: Balance as of September 30, 2017 Related party $ 7,140 $ 7,847 $ 10,000 Others 69,254 73,787 97,000 $ 76,394 $ 81,634 $ 107,000 Balance as of December 31, 2016 Related party $ 11,081 $ 7,564 $ 10,000 Others 107,491 70,810 97,000 $ 118,572 $ 78,374 $ 107,000 The fair value shown above represents the fair value of the debt instrument, inclusive of both the debt and equity components, but excluding the derivative liability. The carrying value represents only the carrying value of the debt component.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company's principal commitments consist of obligations under its outstanding debt obligations, non-cancelable leases for its office space and certain equipment and vendor contracts to provide research services, and purchase obligations under license agreements and reseller agreements. Lease Arrangements The Company leases both real estate and equipment used in its operations and classifies those leases as either operating or capital leases for accounting purposes. As of September 30, 2017 and December 31, 2016 , the Company had no material capital leases and the remaining lives of its operating leases ranged from one to five years . Rental expense associated with operating leases is charged to expense in the year incurred and is included in the Condensed Consolidated Statements of Operations. For the three months ended September 30, 2017 and 2016 , the rental expense was charged to selling, general and administrative expense in the amount of $1,062 and $1,111 , respectively. For the nine months ended September 30, 2017 and 2016 , the rental expense was charged to selling, general and administrative expense in the amount of $3,577 and $3,351 , respectively. Related Party Promissory Note On January 4, 2016, the Company executed a $112,666 demand promissory note in favor of NantCapital to fund the acquisition of NaviNet, On May 9, 2016 and December 15, 2016, the promissory note with NantCapital was amended to provide that all outstanding principal and accrued interest is due and payable on June 30, 2022 and not on demand, and the Promissory Note was subordinated in right of payment to the Convertible Notes (See Note 13). Indenture obligations under Convertible Notes On December 21, 2016, the Company entered into the Indenture relating to the issuance of the $107,000 Convertible Notes, by and between the Company and U.S. Bank National Association the Trustee. The interest rates are fixed at 5.50% per year, payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2021, unless earlier repurchased by the Company or converted pursuant to their terms (See Note 12). Purchase obligations Under License Agreements and Reseller Agreements In September 2016, the Company entered into a Second Amended and Restated Reseller Agreement for genomic and proteomic sequencing services and related bioinformatics and analysis services with NantOmics, with an effective date of June 19, 2015 (See Note 20). In August 2017, the Company and Allscripts modified the amended and restated mutual license and reseller agreement dated June 26, 2015, as amended, such that, among other things, the Company committed to deliver a minimum dollar amount of total bookings over a ten year period (See Note 3). Regulatory Matters The Company is subject to regulatory oversight by the U.S. Food and Drug Administration and other regulatory authorities with respect to the development, manufacturing, and sale of some of the solutions. In addition, the Company is subject to the Health Insurance Portability and Accountability Act (“HIPAA”), the Health Information Technology for Economic and Clinical Health Act and related patient confidentiality laws and regulations with respect to patient information. The Company reviews the applicable laws and regulations regarding effects of such laws and regulations on its operations on an on-going basis and modifies operations as appropriate. The Company believes it is in substantial compliance with all applicable laws and regulations. Failure to comply with regulatory requirements could have a significant adverse effect on the Company’s business and operations. Legal Matters The Company is, from time to time, subject to claims and litigation that arise in the ordinary course of its business. The Company intends to defend vigorously any such litigation that may arise under all defenses that would be available. Except as discussed below, in the opinion of management, the ultimate outcome of proceedings of which management is aware, even if adverse to them, would not have a material adverse effect on the Company’s Condensed Consolidated Financial Condition or Results Of Operations. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Securities Litigation In March 2017, a number of putative class action securities complaints were filed in U.S. District Court for the Central District of California, naming as defendants the Company and certain of its executive officers and directors. These complaints have been consolidated with the lead case captioned Deora v. NantHealth, Inc., 2:17-cv-01825. In June 2017, the lead plaintiffs filed an amended consolidated complaint, which generally alleges that defendants violated federal securities laws by making material misrepresentations in NantHealth’s initial public offering registration statement and in subsequent public statements. In particular, the complaint refers to various third-party articles in alleging that defendants misrepresented NantHealth’s business with the University of Utah, donations to the university by non-profit entities associated with the Company's founder Dr. Soon-Shiong, and orders for GPS Cancer. The lead plaintiffs seek unspecified damages and other relief on behalf of putative classes of persons who purchased or acquired NantHealth securities in the IPO or on the open market from June 1, 2016 through May 1, 2017. Defendants have filed a motion to dismiss. The Company believes that the claims lack merit and intend to vigorously defend the litigation. In May 2017, a putative class action complaint was filed in California Superior Court, Los Angeles County, asserting claims for violations of the Securities Act based on allegations similar to those in Deora . That case is captioned Bucks County Employees Retirement Fund v. NantHealth, Inc. , BC 662330. The parties have agreed to a stay of the case pending resolution of the motion to motion to dismiss in in the federal Deora case . The Company believes that the claims lack merit and intend to vigorously defend the litigation. In August 2017, a putative shareholder derivative action was filed in California Superior Court, Los Angeles County, captioned Engleman v. Soon-Shiong, et al., BC 671261. The complaint contains allegations similar to those in Deora, but asserts causes of action on behalf of NantHealth against various of the Company’s current or former directors and officers for alleged breaches of fiduciary duty, abuse of control, gross mismanagement, and unjust enrichment. The Company is named solely as a nominal defendant. The Company has filed a motion to dismiss the case based on a provision in the Company's corporate charter requiring derivative actions to be brought in Delaware. The Company believes that the claims lack merit and intend to vigorously defend the litigation. The monetary and other impact of these actions may remain unknown for substantial periods of time. The cost to defend, settle or otherwise resolve these matters may be significant and divert management's attention. The Company cannot assure you that it will prevail in these lawsuits. If the Company is ultimately unsuccessful in these matters, the Company could be required to pay substantial amounts which might materially adversely affect its business, operating results and financial condition.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for income taxes for the three months ended September 30, 2017 and 2016 in continuing operations was $30 and $55 , respectively. The provision for income taxes for the nine months ended September 30, 2017 was $85 and the benefit from income taxes for nine months ended September 30, 2016 was $19,203 , in continuing operations. The tax provision for income taxes for the three and nine months ended September 30, 2017 and September 30, 2016 in continuing operations included an income tax provision for the consolidated group based on an estimated annual effective tax rate. Prior to June 1, 2016 the provision for income taxes consisted of income tax provision for the corporate subsidiaries of NantHealth. For the three and nine months ended September 30, 2016 , the tax benefit was mostly attributed to the reduction of deferred tax liability as a result of the amortization of NaviNet’s purchase accounting intangibles and the conversion of NantHealth from an LLC to a C corporation. The effective tax rates for the three months ended September 30, 2017 and 2016 were a provision of 0.13% and 0.21% in continuing operations, respectively. The effective tax rates for the nine months ended September 30, 2017 and 2016 were a provision of 0.08% and a benefit of 17.25% in continuing operations, respectively. The effective tax rate for the three and nine months ended September 30, 2017 differed from the U.S. federal statutory rate of 34% primarily as a result of nondeductible expenses, state income taxes, foreign income tax rate differential and the impact of a full valuation allowance on its net deferred tax assets. The effective tax rate for the three and nine months ended September 30, 2016 differed from the federal statutory rate primarily due to the fact that Nant Health, LLC was a limited liability company during most of that period. It converted from a pass-through entity to a C corporation, NantHealth, Inc., on June 1, 2016. Prior to the LLC Conversion, the tax provision represented that of Nant Health, LLC’s corporate subsidiaries. The Company has evaluated all available evidences supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. and certain foreign jurisdictions. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. If/when the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period(s) such determination is made. The Company files income tax returns in the U.S. Federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. One of the Company’s corporate subsidiary, Assisteo Holding, Inc, has recently completed an IRS audit for the tax year 2014 with no significant adjustments. The Company is no longer subject to income tax examination by the U.S. federal, state or local tax authorities for years ended December 31, 2012 or prior, however, its tax attributes, such as net operating loss (“NOL”) carryforwards and tax credits, are still subject to examination in the year they are used.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Allscripts Stock As discussed in Note 3, Allscripts conveyed to the Company 15,000,000 shares of Company's common stock at par value of $0.0001 per share that were previously owned by Allscripts as consideration for the acquired Business upon Disposition. Initial Public Offering On June 7, 2016, the Company completed its IPO of 6,500,000 shares of common stock at a public offering price of $14.00 per share. Additionally, on June 9, 2016, the underwriters partially exercised their overallotment option to purchase an additional 400,000 shares of the common stock at $14.00 per share. The Company received $83,566 in proceeds from its IPO, after deducting underwriting discounts and commissions and offering costs of $13,034 . In connection with the pricing of the Company’s IPO on June 1, 2016, $40,590 of principal and accrued interest on the Company’s related party promissory notes with NantOmics was converted into 2,899,297 shares of the Company’s common stock. On July 25, 2016, the Company issued 1,056,689 shares of common stock, after withholding approximately 538,794 shares to satisfy tax withholding obligations, to participants of the Phantom Unit Plan based in the United States whose phantom units vested as a result of the IPO. The Company made a cash payment of $5,738 to cover employee withholding taxes upon the settlement of these vested phantom units. The Company also paid $235 on August 9, 2016 to cash-settle 16,818 vested phantom units held by participants of the Phantom Unit Plan at the time of the IPO who were based outside of the United States. LLC Conversion and Reverse Split Upon completion of the LLC Conversion on June 1, 2016, (a) all of the Company’s outstanding units automatically converted into shares of common stock, based on the relative rights of the Company's pre-IPO equityholders as set forth in the Company's limited liability company agreement (the "LLC Agreement") and (b) the Company adopted and filed a certificate of incorporation with the Secretary of State of the state of Delaware and adopted bylaws. The Company adopted and filed an amendment to its certificate of incorporation (the "Amended Certificate of Incorporation") with the Secretary of State of the state of Delaware to effect a 1 -for- 5.5 reverse stock split of its common stock on June 1, 2016. Below is a summary of the number of member units pre LLC Conversion as converted into common shares: Pre Conversion (Units) Former Series A Unit Holders 420,255,676 Former Series B Unit Holders 19,109,603 Former Series C Unit Holders 3,470,254 Former Series D Unit Holders 3,572,066 Former Series E Unit Holders 35,720,664 Former Series G Unit Holders 59,099,908 Former Series H Unit Holders 15,513,726 Total Member Units 556,741,897 The units in the table above were converted to 99,661,906 shares of common stock, of which 10,462 shares of restricted stock. The members’ equity balance of $525,388 was reclassified into common stock and additional paid-in capital in the Condensed Consolidated Balance Sheet as of June 1, 2016. LLC Agreement and Amended Certificate of Incorporation Prior to the LLC Conversion, the Company’s operations were governed by its LLC Agreement. Upon the consummation of the LLC Conversion, the Company converted into a corporation, and the LLC Agreement no longer governs the Company's operations or the rights of its equityholders. The LLC Agreement provided that the board of directors had the power and discretion to manage and control the business, property and affairs of the company, but that certain actions required the consent of certain of the Company's former members. Under the LLC Agreement, the Company had units authorized, including Series A through H units. Each equityholder holding Series A, B, D, E, F, G or H units had one vote for each unit held. Profits interests units awarded under the Nant Health, LLC Profits Interests Plan (the "Profits Interests Plan") took the form of Series C units of the Company. Holders of Series C units did not have the right to vote. The LLC Agreement also set forth the rights of and restrictions on unitholders, including certain rights of first refusal and preemptive and co-sale rights. The LLC Agreement also provided that, upon the LLC Conversion, the allocation of shares of the Company's common stock among the pre-IPO equityholders was dependent upon the IPO price of its common stock, based on the relative rights of the pre-IPO equityholders as set forth in the LLC Agreement. As a result, as part of the LLC Conversion, the Company set the actual allocation of shares among its pre-IPO equityholders based upon the IPO price of its common stock. Concurrently with the consummation of the LLC Conversion, the LLC Agreement was terminated, other than certain provisions relating to certain pre-termination tax matters and certain liabilities. In accordance with the Company’s amended and restated certificate of incorporation, which was filed immediately following the closing of its IPO, the Company is authorized to issue 750,000,000 shares of common stock, with a par value of $0.0001 per share, and 20,000,000 shares of undesignated preferred stock, with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share held on all matters submitted to a vote of its stockholders. Holders of the Company’s common stock have no cumulative voting rights. Further, as of September 30, 2017 and December 31, 2016 , holders of the Company’s common stock have no preemptive, conversion, redemption or subscription rights and there are no sinking fund provisions applicable to the Company’s common stock. Upon liquidation, dissolution or winding-up of the Company, holders of the Company’s common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of the Company’s common stock are entitled to receive dividends, if any, as may be declared from time to time by the Company’s board of directors. As of September 30, 2017 and December 31, 2016 , there were no outstanding shares of preferred stock. 2016 NaviNet Equity Issuances On January 1, 2016, the Company issued 15,513,726 Series H units to 3BE Holdings, LLC for the acquisition of NaviNet at a purchase price of $3.3841 per unit for an aggregate amount of $52,500 . The Series H units had substantially the same rights and preferences as the former Series B, D, E, F and G units that were outstanding at the time. On June 1, 2016, the Series H units issued to 3BE Holdings, LLC were converted into 3,749,998 shares of the Company’s common stock. Other Equity Contributions In January 2015, the Company entered into an agreement to provide certain research related sequencing services to a research institution. The agreement provides that the institution pay the Company $10,000 in exchange for the Company providing sequencing services. Certain public and private charitable 501(c)(3) non-profit organizations provided partial funding for the sequencing and related bioinformatics costs associated with the project. The Company’s Chairman and CEO serves as the CEO and a member of the board of directors of each of the non-profit organizations and by virtue of these positions he may have influence or control over these organizations. The institution was not contractually or otherwise required to use the Company’s molecular profiling solutions or any of the Company’s other products or services as part of the charitable gift, however, the institution did not have a requirement to order or pay for the services unless it first received private donor funding for the project. As a result, the Company does not classify the fees related to this project as revenue but instead classifies the amounts as deemed capital contributions from the Company's Chairman and CEO. During the three and nine months ended September 30, 2016, $1,800 and $3,420 , respectively was recorded as a deemed capital contribution within members' equity or stockholders' equity, and through December 31, 2016 the total $10,000 amount was recorded as a deemed capital contribution within members' equity or stockholders' equity. During the three and nine months ended September 30, 2016 , $1,080 and $2,052 , respectively of costs were recorded as other services cost of revenue related to the service performed. In December 2016, the Company entered into an agreement to provide genomic and proteomic sequencing and related bioinformatics services to an institution related to cancer research. The agreement provides that the institution pay the Company a fixed per-test fee in exchange for the services to be provided by the Company. A private charitable 501(c)(3) non-profit organization controlled by the Company’s Chairman and CEO also made a charitable gift to the institution in December 2016. The gift does not contractually or otherwise require the institution to use the Company’s molecular profiling solutions or any of the Company’s other products or services. No amounts related to this arrangement have been recognized in the Company’s Condensed Consolidated Balance Sheets or Statements of Operations as of or for the three and nine months ended September 30, 2017 . During July 2017, the agreement with the institution was canceled. Redeemable Series F Units / Common Stock On June 20, 2014, the Kuwait Investment Office (“KIO”) purchased 53,580,996 Series F units of the Company through a Delaware blocker corporation, KHealth Holdings, Inc. (“KHealth”), at a purchase price of $2.7995 per unit for an aggregate amount of $150,000 . KIO is the London Office of the Kuwait Investment Authority (“KIA”). As part of the investment, KIO had the right and option, but not the obligation, to require NantHealth to redeem 100% of the outstanding shares of KHealth at an amount equal to the original purchase price of $150,000 plus accrued annual interest of 7.0% if the Company had not (i) filed a registration statement on Form S-1 with the Securities and Exchange Commission on or before December 20, 2015 or (ii) had not completed a qualified initial public offering on or before June 20, 2016 (the “Put Right”). KIO did not exercise the Put Right, and it expired as of June 20, 2016. As of December 31, 2015, the Company determined that the redemption of the Series F units was probable due to the uncertainty of completing a qualified initial public offering under prong (ii) and, as such, accrued $16,042 of interest as a reduction to members’ equity. Prior to December 31, 2015, the Company had concluded that redemption was not probable and had not adjusted the carrying value of such units to redemption value. The Series F units were classified in the Condensed Consolidated balance sheet as of December 31, 2015 as temporary equity as a result of the contingent redemption feature. As part of the LLC Conversion, the Series F units converted to 10,714,285 shares of redeemable common stock as of June 1, 2016. Since the Put Right expired unexercised on June 20, 2016, the shares of common stock owned by KIO are no longer redeemable and are included in Stockholders’ equity. Letter Agreement with NantWorks On May 22, 2016, the Company signed a letter agreement with NantWorks whereby NantWorks agreed to purchase directly from KIO all of the outstanding shares of KHealth if KIO had elected to exercise its Put Right. KIO did not exercise its Put Right (which expired by its terms on June 20, 2016) and NantWorks, therefore did not purchase these shares. The change in net carrying amount of the Series F units and common stock owned by KIO through June 20, 2016 consisted of the following: Redeemable Series F Units Redeemable Common Stock Common Stock and Additional-Paid-in-Capital Balance at December 31, 2015 $ 166,042 $ — $ — Accretion to redemption value 2,625 — — Balance at March 31, 2016 168,667 — — Accretion to redemption value 1,750 — — Balance at June 1, 2016 pre-LLC Conversion 170,417 — — LLC Conversion (170,417 ) 170,417 — Balance at June 1, 2016 post-LLC Conversion — 170,417 — Accretion to redemption value — 583 — Balance at June 20, 2016 pre expiration of Put Right — 171,000 — Expiration of Put Right at June 20, 2016 — (171,000 ) 171,000 Balance at June 20, 2016 post expiration of Put Right $ — $ — $ 171,000

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Based Compensation	Stock Based Compensation The following table reflects the components of stock-based compensation expense recognized in the Company's Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Series C / Restricted Stock - Research and development $ 34 $ 45 $ 80 $ (225 ) Phantom units: Cost of revenue (239 ) (122 ) 247 4,613 Selling, general and administrative (11 ) 2,433 (655 ) 24,288 Research and development 44 1,220 (110 ) 11,779 Discontinued operations (4,792 ) 1,618 1,618 (3,591 ) 8,527 Total phantom units stock-based compensation expense (4,998 ) 5,149 (4,109 ) 49,207 Stock options - Selling, general and administrative 2 — (47 ) — Total stock based compensation expense (4,962 ) 5,194 (4,076 ) 48,982 Amount capitalized to internal-use software and deferred implementation costs (68 ) 1,594 661 1,594 Total stock-based compensation cost $ (5,030 ) $ 6,788 $ (3,415 ) $ 50,576 Retired Profits Interests Plan On December 3, 2013, the Company adopted the Profits Interests Plan under which it had reserved an aggregate of 63,750,000 Series C units for issuance to associates, consultants and contractors of the Company in consideration for bona fide services provided to the Company. The Series C units were considered profits interests of the Company and did not entitle their holders (the “Series C Members”) to receive distributions if the Company were liquidated immediately after the grant. Instead, the Series C Members were entitled to receive an allocation of a portion of the profit and loss of the Company arising after the date of the grant and, subject to vesting conditions, distributions made out of a portion of the profits of the Company arising after the grant date of the Series C units. Grants of the Series C units were either fully vested, partially vested, or entirely unvested at the time of the grant as determined by the Board. Series C Members were not entitled to receive any distributions until the aggregate distributions made by the Company exceeded a hurdle amount applicable to those Series C units. The hurdle amount for each grant was determined by the Board at the date of issuance of such units. After all other members received their applicable hurdle amount, the Series C Members were entitled to receive their percentage interest of such excess distributions. As of December 31, 2015 and through the date of the LLC Conversion, the Company had 3,470,254 Series C units outstanding. Upon the LLC Conversion (See Note 16) on June 1, 2016, the Company issued 28,973 shares of common stock to holders of vested Series C units and 10,462 shares of restricted stock to holders of unvested Series C units. The shares of restricted stock issued to holders of unvested profits interests are subject to forfeiture until becoming fully vested in accordance with the terms of the original Series C unit grant agreements (See Restricted Stock below). Phantom Unit Plan On March 31, 2015, the Company approved the Nant Health, LLC Phantom Unit Plan (the “Phantom Unit Plan”). The maximum number of phantom units that may be issued under the Phantom Plan is equal to 11,590,909 minus the number of issued and outstanding Series C units of the Company. As of September 30, 2017 , there were 1,651,090 phantom units outstanding under the Phantom Unit Plan, after giving effect to the 1 -for- 5.5 reverse stock split. Each grant of phantom units made to a participant under the Phantom Unit Plan vests over a defined service period, subject to completion of a liquidity event. The Company’s IPO satisfied the liquidity event condition and the phantom units now entitle their holders to cash or non-cash payments in an amount equal to the number of vested units held by that participant multiplied by the fair market value of one share of the Company’s common stock on the date each phantom unit vests. After the Company’s IPO, the Company will no longer issue any units under the Phantom Unit Plan. The Company intends to settle all vested phantom unit payments held by United States-based participants in shares of the Company’s common stock and classifies these awards as equity awards in its Condensed Consolidated Balance Sheet. Awards held by participants who are based outside of the United States will be settled in cash and are classified within accrued and other current liabilities on the Condensed Consolidated Balance Sheet as of September 30, 2017 and December 31, 2016 . The following table summarizes the activity related to the unvested phantom units during the nine months ended September 30, 2017 : Number of Units Weighted Average Grant date value per phantom unit Unvested phantom units outstanding - December 31, 2016 4,322,080 $ 14.95 Granted 113,656 $ 4.75 Vested (1,153,593 ) $ 14.57 Forfeited (692,334 ) $ 14.79 Unvested phantom units outstanding - June 30, 2017 2,589,809 $ 14.66 Granted — $ — Vested (21,651 ) $ 15.86 Forfeited (917,068 ) $ 14.84 Unvested phantom units outstanding - September 30, 2017 1,651,090 $ 14.56 During the three and nine months ended September 30, 2016 , the Company granted 995,364 phantom units to employees of related companies who are providing services to the Company under the shared services agreement with NantWorks (See Note 20) as well as certain consultants of the Company. Stock compensation expense for the phantom units issued to these participants is re-measured at the end of each reporting period until the awards vest. All other grants of phantom units have been made to employees of the Company. The Company uses the accelerated attribution method to recognize expense for all phantom units since the awards’ vesting was subject to the completion of a liquidity event. The grant date fair value of the phantom units granted prior to LLC Conversion was estimated using both an option pricing method and a probability weighted expected return method. As of September 30, 2017 , the Company had $6,547 of unrecognized stock based compensation expense related to phantom units which will be recognized over a weighted-average period of 1.6 years . Of that amount, $5,853 of unrecognized expense is related to employee grants with a weighted-average period of 1.5 years and $694 of unrecognized expense is related to non-employee grants with a weighted-average period of 1.7 years . During the three and nine months ended September 30, 2017 , the Company issued 9,906 and 713,269 shares, respectively, of common stock to participants of the Phantom Unit Plan based in the United States, after withholding approximately 6,796 and 397,752 shares, respectively, to satisfy tax withholding obligations. The Company made a cash payment of $29 and $2,739 to cover employee withholding taxes upon the settlement of these vested phantom units during the three and nine months ended September 30, 2017 , respectively. During the three and nine months ended September 30, 2017 the Company also paid $0 and $300 , respectively, to cash-settle 2 and 59,276 vested phantom units, respectively, held by participants of the Phantom Unit Plan based outside of the United States, and to pay cash in lieu of fractional shares for vested units held by participants based in the United States. 2016 Equity Incentive Plan In May and June of 2016, the Company’s Board of Directors adopted and the Company’s stockholders approved the 2016 Equity Incentive Plan (“the 2016 Plan”) in connection with the Company’s IPO. The 2016 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to employees, directors and consultants. A total of 6,000,000 shares of common stock were reserved for issuance pursuant to the 2016 Plan. Restricted Stock The Company issued 10,462 shares of restricted stock under the 2016 Plan on June 1, 2016, in connection with the conversion of the Series C units, of which 3,486 were vested and converted into unrestricted common stock during 2016, and as of September 30, 2017 and December 31, 2016 there were 6,976 shares of restricted stock. Total stock-based compensation expense of $145 is expected to be recognized on a straight-line basis over approximately the next 1.1 years for the unvested restricted stock outstanding as of September 30, 2017 . The unrecognized stock compensation relates to nonemployees and the awards are being accounted for pursuant to ASC 505-50. Stock compensation expense for the Series C units/restricted stock issued to the nonemployees is calculated based on the fair value of the award on each balance sheet date and the attribution of that cost is being recognized ratably over the vesting period. Stock Options During the year ended December 31, 2016, the Company issued 500,000 stock options under the 2016 equity incentive plan to Mark Burnett, who is a non-employee member of the Company’s Board of Directors, with exercise price of $14.00 . The award is being accounted for pursuant to ASC 505-50. Stock compensation expense issued to the nonemployees is calculated based on the fair value of the award on each balance sheet date and the attribution of that cost is being recognized ratably over the vesting period. The Company has utilized the Black-Scholes option-pricing model to determine the fair value of the stock options. As of September 30, 2017 , the Company had $21 of unrecognized stock based compensation expense related to the stock options. This cost is expected to be recognized over a weighted-average period of 2.65 years.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2017
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring Concurrent with the sale to Allscripts (See Note 3), the Company performed a reorganization of its operations intended to improve efficiency and better align the Company's costs and employment structure with its strategic plans. The reorganization includes a workforce reduction. Upon signing release agreements, impacted employees were eligible to receive severance payments in specified amounts, and general benefits for specified periods in accordance with our policies and local requirements. In the three and nine months ended September 30, 2017, the Company recorded restructuring charges of approximately $1,340 associated with the termination of the employees. In connection with the termination, the Company reversed previously estimated stock based compensation of $1,549 as a result of the forfeiture of unvested awards. The Company recorded these charges in cost of revenue, general and administrative, and research and development expenses based on responsibilities of the impacted employees. The Company recorded $362 and $2,298 of restructuring charges related to reduction in employees in the three months and nine months ended September 30, 2016, respectively. The Company's restructuring accrual activity for the nine months ended September 30, 2017 is summarized as follows: Balance as of December 31, 2016 Expenses, Net Cash Balance as of September 30, 2017 Employee severance and other personnel benefits liability $ — $ 1,340 $ (1,028 ) $ 312

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net income (loss) per share of common stock and redeemable common stock for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 Common Stock Common Stock Redeemable Common Stock Common Stock Common Stock Redeemable Common Stock Net income (loss) per share numerator: Net loss from continuing operations $ (23,015 ) $ (26,392 ) $ — $ (108,839 ) $ (92,106 ) $ — Net loss from discontinued operations (19,383 ) (10,482 ) — (44,738 ) (32,045 ) $ — Total net loss $ (42,398 ) $ (36,874 ) $ — $ (153,577 ) $ (124,151 ) $ — Accretion to redemption value of series F/redeemable common stock — — — — (4,958 ) 4,958 Net income (loss) for basic and diluted net income (loss) per share $ (42,398 ) $ (36,874 ) $ — $ (153,577 ) $ (129,109 ) $ 4,958 Net income (loss) per share denominator: Weighted-average shares for basic net loss per share 115,924,122 121,245,440 — 119,745,231 108,359,973 6,686,653 Effect of dilutive securities — — — — — — Weighted-average shares for dilutive net income (loss) per share 115,924,122 121,245,440 — 119,745,231 108,359,973 6,686,653 Basic and diluted net loss per share from continuing operations $ (0.20 ) $ (0.22 ) $ — $ (0.91 ) $ (0.90 ) N/A Basic and diluted net loss per share from discontinued operations $ (0.17 ) $ (0.08 ) $ — $ (0.37 ) $ (0.29 ) N/A Basic and diluted total net loss per share $ (0.37 ) $ (0.30 ) $ — $ (1.28 ) $ (1.19 ) $ 0.74 The net income (loss) per share and weighted-average shares outstanding have been computed to give effect to the LLC Conversion (See Note 16) that occurred June 1, 2016 prior to the Company’s initial public offering. In conjunction with the LLC Conversion, (a) all of the Company’s outstanding units automatically converted into shares of common stock, based on the relative rights of the Company's pre-IPO equityholders as set forth in the limited liability company agreement and (b) the Company adopted and filed a certificate of incorporation with the Secretary of State of the state of Delaware and adopted bylaws. The Company filed an amended certificate of incorporation to effect a 1 -for- 5.5 reverse stock split of its common stock on June 1, 2016. As of December 31, 2015, the Company determined that the redemption of the Series F units was probable due to the uncertainty of completing a qualified initial public offering and, as such, accrued interest as a reduction to members’ equity. Prior to December 31, 2015, the Company had concluded that redemption was not probable and had not adjusted the carrying value of such units to redemption value. As of June 1, 2016 as part of the LLC Conversion, the Series F units converted to shares of redeemable common stock. The Put Right on redeemable common stock expired unexercised on June 20, 2016, and as of that date, the shares of common stock owned by KIO are no longer redeemable and are included in common shares (See Note 16). The following number of potential common shares at the end of each period were excluded from the calculation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive for the periods presented: Three and Nine Months Ended 2017 2016 Unvested restricted stock 6,976 10,462 Unvested phantom units 1,651,090 4,561,255 Stock options 500,000 — Convertible notes 8,815,655 —

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions NantWorks Shared Services Agreement In October 2012, the Company entered into a shared services agreement with NantWorks that provides for ongoing services from NantWorks in areas such as public relations, information technology and cloud services, human resources and administration management, finance and risk management, environmental health and safety, sales and marketing services, facilities, procurement and travel, and corporate development and strategy (the "Shared Services Agreement"). The Company is billed quarterly for such services at cost, without mark-up or profit for NantWorks, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services. During the three and nine months ended September 30, 2017 , the Company incurred $961 and $4,026 of expenses, respectively, related to selling, general and administrative services provided to the Company by NantWorks and affiliates, net of services provided to NantWorks and affiliates. During the three and nine months ended September 30, 2016 , the Company incurred $2,106 and $7,692 of expenses, respectively, related to selling, general and administrative services provided to the Company by NantWorks and affiliates, net of services provided to NantWorks and affiliates. Additionally, the Company incurred $0 and $239 of expenses during the three and nine months ended September 30, 2017 , respectively related to research and development services provided by NantWorks and its subsidiaries and incurred $204 and $414 of expenses during the three and nine months ended September 30, 2016 , related to research and development services provided by NantWorks and its subsidiaries. Related Party Receivables and Payables As of September 30, 2017 and December 31, 2016 , the Company had related party receivables, net of related party payables of $2,298 and $2,664 , respectively, primarily consisting of a receivable from Ziosoft KK of $2,082 and $2,126 , respectively, which was related to the sale of Qi Imaging. As of September 30, 2017 and December 31, 2016 the Company had related party payables, net of receivables balances, and related party liabilities of $15,513 and $13,694 , respectively, which primarily relate to amounts owed to NantWorks pursuant to the Shared Services Agreement, amounts owed to NantOmics under the Second Amended Reseller Agreement (defined below) and interest payable. The balance of the related party receivables and payables represent amounts paid by affiliates on behalf of the Company or vice versa. Amended Reseller Agreement On June 19, 2015, the Company entered into a five and a half year exclusive Reseller Agreement with NantOmics for sequencing and bioinformatics services (the "Original Reseller Agreement"). NantOmics is a majority owned subsidiary of NantWorks and is controlled by the Company's Chairman and CEO. On May 9, 2016, the Company and NantOmics executed an Amended and Restated Reseller Agreement (the “Amended Reseller Agreement”), pursuant to which the Company received the worldwide, exclusive right to resell NantOmics’ quantitative proteomic analysis services, as well as related consulting and other professional services, to institutional customers (including insurers and self-insured healthcare providers) throughout the world. The Company retained its existing rights to resell NantOmics’ genomic sequencing and bioinformatics services. Under the Amended Reseller Agreement, the Company is responsible for various aspects of delivering its sequencing and molecular analysis solutions, including patient engagement and communications with providers such as providing interpretations of the reports delivered to the physicians and resolving any disputes, ensuring customer satisfaction, and managing billing and collections. On September 20, 2016, the Company and NantOmics further amended the Reseller Agreement (the "Second Amended Reseller Agreement"). The Second Amended Reseller Agreement permits the Company to use vendors other than NantOmics to provide any or all of the services that are currently being provided by NantOmics and clarifies that the Company is responsible for order fulfillment and branding. The Second Amended Reseller Agreement grants to the Company the right to renew the agreement (with exclusivity) for up to three renewal terms, each lasting three years , if the Company achieves projected volume thresholds, as follows: (i) the first renewal option can be exercised if the Company completes at least 300,000 tests between June 19, 2015 and June 30, 2020; (ii) the second renewal option can be exercised if the Company completes at least 570,000 tests between July 1, 2020 and June 30, 2023; and (iii) the third renewal option can be exercised if the Company completes at least 760,000 tests between July 1, 2023 and June 30, 2026. If the Company does not meet the applicable volume threshold during the initial term or the first or second exclusive renewal terms, the Company can renew for a single additional three year term, but only on a non-exclusive basis. The Company agreed to pay NantOmics non-cancellable annual minimum fees of $2,000 per year for each of the calendar years from 2016 through 2020 and, subject to the Company exercising at least one of its renewal options described above, the Company is required to pay annual minimum fees to NantOmics of at least $25,000 per year for each of the calendar years from 2021 through 2023 and $50,000 per year for each of the calendar years from 2024 through 2029. As of September 30, 2017 and December 31, 2016 , the Company has $1,083 and $1,950 , respectively, of outstanding related party payables under the Second Amended Reseller Agreement. During the three and nine months ended September 30, 2017 , $1,549 and $3,937 , respectively of direct costs were recorded as cost of revenue related to the Second Amended Reseller Agreement. During the three and nine months ended September 30, 2016 , $1,651 and $2,982 , respectively of direct costs were recorded as cost of revenue related to the Second Amended Reseller Agreement. Cambridge Purchase Agreement On December 15, 2016, the Company entered into a purchase agreement (the “Cambridge Purchase Agreement”) with Cambridge Equities, L.P., an entity affiliated with the Company's Chairman and CEO Dr. Patrick Soon-Shiong (“Cambridge”), to issue and sell $10,000 in aggregate principal amount of the Convertible Notes in a private placement pursuant to an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act. The Cambridge Purchase Agreement includes customary representations, warranties and covenants by the Company and customary closing conditions (See Note 12). The accrued and unpaid interest on the convertible notes was $162 and $15 at September 30, 2017 and December 31, 2016 , as part of current related party liabilities on the Condensed Consolidated Balance Sheet. Related Party Promissory Notes On January 4, 2016, the Company executed a $112,666 demand promissory note in favor of NantCapital to fund the acquisition of NaviNet. The note bears interest at a per annum rate of 5.0% , compounded annually and computed on the basis of the actual number of days elapsed and a year of 365 or 366 days, as the case may be. The unpaid principal and any accrued and unpaid interest on the note was originally due and payable on demand in either (i) cash, (ii) shares of the Company's common stock based on per share price of $18.6126 , (iii) Series A-2 units of NantOmics based on a per unit price of $1.484 to the extent such equity is owned by the Company or (iv) any combination of the foregoing, all at the option of NantCapital. Subject to the preceding sentence, the Company may prepay the outstanding amount at any time, either in whole or in part, without premium or penalty and without the prior consent of NantCapital. On May 9, 2016, the promissory note with NantCapital was amended to provide that all outstanding principal and accrued interest is due and payable on June 30, 2021, and not on demand. On December 15, 2016, in connection with the offering of the Convertible Notes, the Company entered into a Second Amended and Restated Promissory Note which amends and restates the Amended and Restated Promissory Note, dated May 9, 2016, between the Company and NantCapital, to, among other things, extend the maturity date of the Promissory Note to June 30, 2022 and to subordinate the Promissory Note in right of payment to the Convertible Notes (See Note 12 ). No other terms of the promissory note were changed. As of September 30, 2017 and December 31, 2016 , the total principal and interest outstanding on the note amounted to $122,675 and $118,253 , respectively. The accrued and unpaid interest on the note was $10,009 and $5,587 , respectively as of September 30, 2017 and December 31, 2016 , as part of non current related party liabilities on the Condensed Consolidated Balance Sheets. The Company can request additional advances subject to NantCapital approval. The NantCapital Note bears interest at a per annum rate of 5.0% compounded annually and computed on the basis of the actual number of days in the year. NantCapital has the option, but not the obligation, to require us to repay any such amount in cash, Series A-2 units of NantOmics (based on a per unit price of $1.484 ) held by us, shares of the Company's common stock based on a per share price of $18.6126 (if such equity exists at the time of repayment), or any combination of the foregoing at the sole discretion of NantCapital. On January 22, 2016, the Company executed a demand promissory note in favor of NantOmics. The principal amount of the initial advance totaled $20,000 . On March 8, 2016, NantOmics made a second advance to the Company for $20,000 . The note bears interest at a per annum rate is 5.0% and is compounded annually. In May and June of 2016, the Company executed amendments to the demand promissory note with NantOmics, which provide that all unpaid principal of each advance owed to NantOmics and any accrued and unpaid interest would convert automatically into shares of the Company’s common stock after pricing of the Company’s IPO and immediately after conversion of the Company from a limited liability company to a corporation. On June 1, 2016, approximately $40,590 of principal and accrued interest under the promissory note with NantOmics was converted into 2,899,297 shares of the Company’s common stock in connection with the IPO. The Company can request additional advances subject to NantOmics approval, and as of September 30, 2017 , there was no outstanding balance on the promissory note.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of NantHealth and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These interim Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). These Financial Statements have been prepared on the same basis as the audited Consolidated Financial Statements for the fiscal year ended December 31, 2016 and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company's financial position and results of operation. The results of operations of the entities disposed of are included in the unaudited condensed consolidated financial statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. Certain reclassifications have been made to prior period amounts to conform to the current year presentation. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2016 has been derived from the audited Consolidated Financial Statements at that date but does not include all of the disclosures required by GAAP. Assets and liabilities of the discontinued operations are presented separately in the asset and liability sections of the prior period balance sheet. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year. The Company believes its existing cash, cash equivalents and ability to borrow from affiliated entities under existing facilities will be sufficient to fund operations through at least the next 12 months. If these sources are insufficient to satisfy the Company's liquidity requirements, it may seek to sell additional equity, through one or more follow-on public offerings or in separate financings, or sell additional debt securities or obtain a credit facility. Further, because of the risk and uncertainties associated with the commercialization of the Company's existing products as well as products in development, the Company may need additional funds to meet its needs sooner than planned. To date, the Company's primary sources of capital were private placement of membership interests prior to its IPO, debt financing agreements, including the promissory note with NantCapital, LLC (“NantCapital”), convertible notes, and its IPO.
Principles of Consolidation	Principles of Consolidation The accompanying Condensed Consolidated Financial Statements include the financial statements of the Company and its wholly owned subsidiaries. All intercompany balances and transactions with the Company’s subsidiaries have been eliminated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Segment Reporting	Segment Reporting The chief operating decision maker for the Company is its Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a Condensed Consolidated basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, or plans for levels or components below the Condensed Consolidated unit level. Accordingly, management has determined that the Company operates in one reportable segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue from Contracts with Customers The new FASB Topic 606 standards commencing with Accounting Standard Update ("ASU") No. 2014-09 ("Topic 606"), Revenue from Contracts with Customers replace existing revenue recognition rules including industry-specific guidance. Topic 606 outlines a five-step process for revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards, and also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Major provisions include determining which goods and services are distinct and require separate accounting (performance obligations), how variable consideration (which may include change orders and claims) is recognized, whether revenue should be recognized at a point in time or over time and ensuring the time value of money is considered in the transaction price. Revenue is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for goods or services. The provisions of Topic 606 will become effective for annual reporting periods beginning after December 15, 2017. The FASB allows two adoption methods under Topic 606 standards. Under one method, a company will apply the rules to contracts in all reporting periods presented, subject to certain allowable exceptions. Under the other method, a company would apply the rules to all contracts existing as of January 1, 2018, recognizing in the opening balance of retained earnings an adjustment for the cumulative effect of the change and providing additional disclosures comparing results to previous rules. As permitted under the standard, the Company plans to adopt ASU 2014-09 in the first quarter of 2018 using the modified retrospective approach and to recognize the cumulative effect of existing contracts in the opening balance of retained earnings on the effective date of January 1, 2018. The Company continues to assess the impact of the new revenue standard on the current business processes, systems and controls. Upon initial evaluation, the Company expects that one significant impact will likely be to its software arrangements due to the requirement to estimate the selling price for deliverables. Under current revenue accounting guidance, if VSOE does not exist for license and implementation fees, the Company recognizes those revenues over the post contract support period. Also, the principal versus agent analysis under Topic 606 focuses on whether the entity controls each specified good or service in an arrangement and the company is currently evaluating whether the guidance will have an impact on how the Company reports its sequencing and molecular analysis revenue. The Company is also assessing the impact of capitalizing costs associated with obtaining customer contracts, specifically commission and incentive payments. Currently, these payments are expensed in the period they are incurred. Under the updated guidance, certain of these payments may be deferred on the Company's Condensed Consolidated Balance Sheets and amortized over the expected life of the customer contract. Other accounting pronouncements In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): C larifying the Definition of a Business . This standard clarifies the definition of a business and provides a screen to determine if a set of inputs, processes and outputs is a business. The screen requires that when substantially all of the fair value of gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the assets acquired would not be a business. Under the new guidance, in order to be considered a business, an acquisition must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output. In addition, the standard narrows the definition of the term “output” so that it is consistent with how it is described in Topic 606 standards. This standard will be effective for annual periods beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently evaluating the impact this guidance may have on its Condensed Consolidated Financial Statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) to simplify the accounting for goodwill impairment. This guidance, among other things, removes step 2 of the goodwill impairment test thus eliminating the need to determine the fair value of individual assets and liabilities of the reporting unit. Upon adoption of this ASU, goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This may result in more or less impairment being recognized than under current guidance. This update will become effective for the Corporation’s annual and interim goodwill impairment tests beginning in the first quarter of 2020, and early adoption is permitted. The Company is still evaluating the impact of this standard update. In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" (“ASU 2016-02”). The update is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. This guidance will become effective for interim and annual reporting periods beginning with the year ending December 31, 2019. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its Condensed Consolidated Financial Statements. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission ("SEC") did not have, or are not believed by management to have, a material impact on the Company's present or future Condensed Consolidated Financial Statements.

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	. The total loss on sale to Allscripts consisted of the following: Cash received as consideration $ 1,742 Estimated costs to be incurred by the Company to fulfill certain customer service obligations of (887 ) Fair value of common stock 42,750 Net consideration received 43,605 Less: Carrying value of net assets sold (55,255 ) Plus: Reclassification of cumulative translation adjustments of foreign subsidiaries 117 Loss from sale of Business $ (11,533 ) The sale of the Business qualified as a discontinued operations because it comprised operations and cash flows that could be distinguished, operationally and for financial reporting purposes, from the rest of the Company. The disposal of the Business represented a strategic shift in the Company’s operations as the sale enables the Company to focus on genomic sequencing, clinical decision support, connected care and payer engagement. The carrying amounts of the major classes of assets and liabilities of the Company's discontinued operations as of December 31, 2016 are as follows: December 31, Cash and cash equivalents $ 2,780 Accounts receivable, net 2,055 Inventories 532 Deferred implementation costs 2,730 Related party receivables, net 206 Prepaid expenses and other current assets 1,689 Current assets of discontinued operations 9,992 Property, plant, and equipment, net 9,010 Deferred implementation costs, net of current 4,709 Goodwill 16,444 Intangible assets, net 40,314 Other assets 206 Total assets of discontinued operations $ 80,675 Accounts payable $ 681 Accrued and other current liabilities 5,199 Deferred revenue 7,616 Current liabilities of discontinued operations 13,496 Deferred revenue, net of current 6,111 Deferred income tax liabilities, net of current 838 Total liabilities of discontinued operations $ 20,445 The operating results of the Company's discontinued operations are as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Major line items constituting income from discontinued operations Net revenue $ 1,498 $ 4,695 $ 7,619 $ 13,740 Cost of revenue 1,787 7,200 16,318 19,300 Selling, general and administrative 1,515 2,681 8,675 10,476 Research and development (372 ) 3,895 7,571 12,352 Amortization of software license and acquisition-related assets 458 760 1,978 2,280 Other (income) expense 216 440 134 527 Loss from sale of Business 11,533 — 11,533 — Gain from dissolution of a business component (860 ) — (860 ) — Loss from discontinued operations, before income taxes (12,779 ) (10,281 ) (37,730 ) (31,195 ) Provision for income taxes 6,604 201 7,008 850 Loss from discontinued operations, net of income taxes $ (19,383 ) $ (10,482 ) $ (44,738 ) $ (32,045 ) . The significant operating and investing cash and non-cash items of the discontinued operations included in the unaudited condensed consolidated statements of cash flows for the nine months ended September 30, 2017 and 2016 were as follows: Nine Months Ended 2017 2016 Depreciation and amortization from discontinued operations $ 8,829 $ 8,645 Loss from sale of Business 11,533 — Proceeds from sale of Business 1,721 — Capital expenditures 4,668 144

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Schedule of Business Acquisitions, Total Purchase Consideration	The following table summarizes the total purchase consideration for the acquisition: Amounts Cash paid to 3BE at closing $ 74,823 Cash paid to option holders after closing 2,580 Cash paid to escrow account 6,126 Working capital settlement payment 455 Fair value of Series H units 52,500 Total consideration $ 136,484
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total consideration was allocated to the net assets acquired based upon their estimated fair values: Amounts Cash and restricted cash $ 4,804 Accounts receivable, net 10,693 Property, plant and equipment 5,044 Other assets and liabilities, net 4,561 Accounts payable (4,585 ) Accrued and other current liabilities (3,674 ) Deferred revenue (2,603 ) Deferred tax liability (15,508 ) Assumed indebtedness (23,324 ) Trade names 3,000 Developed technology 32,000 Customer relationships 52,000 Goodwill 74,076 Total fair value of net assets acquired $ 136,484

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories, net	Inventories as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Finished goods $ 974 $ 1,308 Raw materials — 377 Inventories $ 974 $ 1,685

Prepaid Expenses and Other Cu32

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Other Current Assets And Other Current Liabilities [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Prepaid expenses $ 3,734 $ 3,083 Restricted cash 350 100 Other current assets 140 173 Prepaid expenses and other current assets $ 4,224 $ 3,356
Schedule of Accrued and Other Current Liabilities	Accrued and other current liabilities of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Payroll and related costs $ 8,109 $ 9,821 NaviNet acquisition accrued earnout (See Note 4) 4,736 2,675 Other accrued and other current liabilities 7,123 7,536 Accrued and other current liabilities $ 19,968 $ 20,032

Property, Plant and Equipment33

Property, Plant and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Property, plant and equipment, net as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Computer equipment and software $ 13,956 $ 13,391 Furniture and equipment 3,198 3,169 Leasehold and building improvements 4,230 3,921 Internal use software 15,853 10,371 Construction in progress 1,444 1,090 38,681 31,942 Less: accumulated depreciation and amortization (18,697 ) (11,813 ) Property, plant and equipment, net $ 19,984 $ 20,129

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The Company’s definite-lived intangible assets as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, December 31, Customer relationships $ 52,400 $ 52,400 Developed technologies 61,130 61,130 Trade name 3,000 3,000 116,530 116,530 Less: accumulated amortization (44,909 ) (37,718 ) Intangible assets, net $ 71,621 $ 78,812
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization expense over the next five years and thereafter for the intangible assets that exist as of September 30, 2017 is as follows: Amounts Remainder of 2017 $ 2,197 2018 8,788 2019 8,788 2020 8,038 2021 8,038 Thereafter 35,772 Total future intangible amortization expense $ 71,621

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	The Company used the following summarized financial information for NantOmics for the nine months ended June 30, 2017 and 2016 , respectively, to record its equity method losses for the nine months ended September 30, 2017 and 2016 : Trailing Nine Months Ended June 30, 2017 2016 Sales $ 5,294 $ 2,936 Gross loss (4,330 ) (3,113 ) Loss from operations (33,262 ) (25,693 ) Net loss (41,420 ) (21,841 ) Net loss attributable to NantOmics (39,088 ) (20,273 )

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Convertible Debt	The following table summarizes how the issuance of the Convertible Notes is reflected in the Company's Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016 . Related party Others Total Balance as of September 30, 2017 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (2,153 ) (23,213 ) (25,366 ) Net carrying amount $ 7,847 $ 73,787 $ 81,634 Balance as of December 31, 2016 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (2,436 ) (26,190 ) (28,626 ) Net carrying amount $ 7,564 $ 70,810 $ 78,374
Schedule of Interest Expense	The following table sets forth the Company's interest expense recognized in the Company's Condensed Consolidated Statements of Operations: Three Months Ended September 30, 2017 Nine Months Ended September 30, 2017 Related party Others Total Related party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 $ 412 $ 4,001 $ 4,413 Amortization of debt discounts 94 897 991 275 2,608 2,883 Amortization of deferred financing offering costs 3 127 130 8 369 377 Total convertible notes interest expense $ 234 $ 2,358 $ 2,592 $ 695 $ 6,978 $ 7,673

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016 consisted of the following: September 30, 2017 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets - Cash equivalents $ 64,279 $ 64,279 $ — $ — Liabilities - Interest make-whole derivative 26 — — 26 December 31, 2016 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Assets - Cash equivalents $ 146,287 $ 146,287 $ — $ — Liabilities - Interest make-whole derivative 271 — — 271
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following tables set forth a summary of changes in the fair value of Level 3 liabilities for the three and nine months ended September 30, 2017 : June 30, 2017 Additions Change in fair value September 30, 2017 Interest make-whole derivative liability: Related party $ 3 $ — $ (1 ) $ 2 Others 29 — (5 ) 24 $ 32 $ — $ (6 ) $ 26 December 31, 2016 Additions Change in fair value September 30, 2017 Interest make-whole derivative liability: Related party $ 25 $ — $ (23 ) $ 2 Others 246 — (222 ) 24 $ 271 $ — $ (245 ) $ 26 As of September 30, 2017 and December 31, 2016 , the fair value and carrying value of the Company's Convertible Notes were: Fair value Carrying value Face value 5.5% convertible senior notes due December 15, 2021: Balance as of September 30, 2017 Related party $ 7,140 $ 7,847 $ 10,000 Others 69,254 73,787 97,000 $ 76,394 $ 81,634 $ 107,000 Balance as of December 31, 2016 Related party $ 11,081 $ 7,564 $ 10,000 Others 107,491 70,810 97,000 $ 118,572 $ 78,374 $ 107,000

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Schedule Of Member Units, Pre-Conversion	Below is a summary of the number of member units pre LLC Conversion as converted into common shares: Pre Conversion (Units) Former Series A Unit Holders 420,255,676 Former Series B Unit Holders 19,109,603 Former Series C Unit Holders 3,470,254 Former Series D Unit Holders 3,572,066 Former Series E Unit Holders 35,720,664 Former Series G Unit Holders 59,099,908 Former Series H Unit Holders 15,513,726 Total Member Units 556,741,897
Schedule of Change in Net Carrying Amount of Equity Interests Owned by Buyer	The change in net carrying amount of the Series F units and common stock owned by KIO through June 20, 2016 consisted of the following: Redeemable Series F Units Redeemable Common Stock Common Stock and Additional-Paid-in-Capital Balance at December 31, 2015 $ 166,042 $ — $ — Accretion to redemption value 2,625 — — Balance at March 31, 2016 168,667 — — Accretion to redemption value 1,750 — — Balance at June 1, 2016 pre-LLC Conversion 170,417 — — LLC Conversion (170,417 ) 170,417 — Balance at June 1, 2016 post-LLC Conversion — 170,417 — Accretion to redemption value — 583 — Balance at June 20, 2016 pre expiration of Put Right — 171,000 — Expiration of Put Right at June 20, 2016 — (171,000 ) 171,000 Balance at June 20, 2016 post expiration of Put Right $ — $ — $ 171,000

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following table reflects the components of stock-based compensation expense recognized in the Company's Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Series C / Restricted Stock - Research and development $ 34 $ 45 $ 80 $ (225 ) Phantom units: Cost of revenue (239 ) (122 ) 247 4,613 Selling, general and administrative (11 ) 2,433 (655 ) 24,288 Research and development 44 1,220 (110 ) 11,779 Discontinued operations (4,792 ) 1,618 1,618 (3,591 ) 8,527 Total phantom units stock-based compensation expense (4,998 ) 5,149 (4,109 ) 49,207 Stock options - Selling, general and administrative 2 — (47 ) — Total stock based compensation expense (4,962 ) 5,194 (4,076 ) 48,982 Amount capitalized to internal-use software and deferred implementation costs (68 ) 1,594 661 1,594 Total stock-based compensation cost $ (5,030 ) $ 6,788 $ (3,415 ) $ 50,576
Schedule of Share-based Compensation, Activity	The following table summarizes the activity related to the unvested phantom units during the nine months ended September 30, 2017 : Number of Units Weighted Average Grant date value per phantom unit Unvested phantom units outstanding - December 31, 2016 4,322,080 $ 14.95 Granted 113,656 $ 4.75 Vested (1,153,593 ) $ 14.57 Forfeited (692,334 ) $ 14.79 Unvested phantom units outstanding - June 30, 2017 2,589,809 $ 14.66 Granted — $ — Vested (21,651 ) $ 15.86 Forfeited (917,068 ) $ 14.84 Unvested phantom units outstanding - September 30, 2017 1,651,090 $ 14.56

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2017
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The Company's restructuring accrual activity for the nine months ended September 30, 2017 is summarized as follows: Balance as of December 31, 2016 Expenses, Net Cash Balance as of September 30, 2017 Employee severance and other personnel benefits liability $ — $ 1,340 $ (1,028 ) $ 312

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net income (loss) per share of common stock and redeemable common stock for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 Common Stock Common Stock Redeemable Common Stock Common Stock Common Stock Redeemable Common Stock Net income (loss) per share numerator: Net loss from continuing operations $ (23,015 ) $ (26,392 ) $ — $ (108,839 ) $ (92,106 ) $ — Net loss from discontinued operations (19,383 ) (10,482 ) — (44,738 ) (32,045 ) $ — Total net loss $ (42,398 ) $ (36,874 ) $ — $ (153,577 ) $ (124,151 ) $ — Accretion to redemption value of series F/redeemable common stock — — — — (4,958 ) 4,958 Net income (loss) for basic and diluted net income (loss) per share $ (42,398 ) $ (36,874 ) $ — $ (153,577 ) $ (129,109 ) $ 4,958 Net income (loss) per share denominator: Weighted-average shares for basic net loss per share 115,924,122 121,245,440 — 119,745,231 108,359,973 6,686,653 Effect of dilutive securities — — — — — — Weighted-average shares for dilutive net income (loss) per share 115,924,122 121,245,440 — 119,745,231 108,359,973 6,686,653 Basic and diluted net loss per share from continuing operations $ (0.20 ) $ (0.22 ) $ — $ (0.91 ) $ (0.90 ) N/A Basic and diluted net loss per share from discontinued operations $ (0.17 ) $ (0.08 ) $ — $ (0.37 ) $ (0.29 ) N/A Basic and diluted total net loss per share $ (0.37 ) $ (0.30 ) $ — $ (1.28 ) $ (1.19 ) $ 0.74
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following number of potential common shares at the end of each period were excluded from the calculation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive for the periods presented: Three and Nine Months Ended 2017 2016 Unvested restricted stock 6,976 10,462 Unvested phantom units 1,651,090 4,561,255 Stock options 500,000 — Convertible notes 8,815,655 —

Description of Business and B42

Description of Business and Basis of Presentation (Details) $ / shares in Units, $ in Thousands	Jun. 09, 2016$ / sharesshares	Jun. 07, 2016USD ($)$ / sharesshares	Jun. 01, 2016	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Class of Stock [Line Items]
Reverse stock split, conversion ratio			0.1818
Proceeds from initial public offering, net of offering costs				$ 0	$ 83,566
IPO
Class of Stock [Line Items]
Issuance of membership interests, shares | shares		6,500,000
Offering price per share (usd per share) | $ / shares		$ 14
Proceeds from initial public offering, net of offering costs		$ 83,566
Offering costs for initial public offering		$ 13,034
Over allotment option
Class of Stock [Line Items]
Issuance of membership interests, shares | shares	400,000
Offering price per share (usd per share) | $ / shares	$ 14

Summary of Significant Accoun43

Summary of Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2017segment
Accounting Policies [Abstract]
Number of reportable segments	1

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 29, 2017	Aug. 25, 2017	Aug. 03, 2017	Sep. 30, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Common stock, par value (usd per share)				$ 0.0001	$ 0.0001
NantHealth, Inc.'s Provider/Patient Engagement Solutions Business | Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shares received for sale of provider/patient engagement solutions business (shares)			15,000,000
Common stock, par value (usd per share)				$ 0.0001
Cash consideration as an estimated working capital payment		$ 1,742
Potential additional cash consideration		1,110
Plus: Reclassification of cumulative translation adjustments of foreign subsidiaries		$ 117
Period minimum dollar bookings to be delivered		10 years
Net.Orange Ltd | Discontinued Operations, Disposed of by Means Other than Sale, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Plus: Reclassification of cumulative translation adjustments of foreign subsidiaries	$ 860

Discontinued Operations - Loss

Discontinued Operations - Loss on Sale (Details) - USD ($) $ in Thousands	Aug. 25, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from sale of Business		$ (10,673)	$ 0
Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Less: Carrying value of net assets sold				$ (80,675)
NantHealth, Inc.'s Provider/Patient Engagement Solutions Business | Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received as consideration	$ 1,742
Estimated costs to be incurred by the Company to fulfill certain customer service obligations of the Business post-closing	(887)
Fair value of common stock	42,750
Net consideration received	43,605
Less: Carrying value of net assets sold	(55,255)
Plus: Reclassification of cumulative translation adjustments of foreign subsidiaries	117
Loss from sale of Business	$ (11,533)

Discontinued Operations - Asset

Discontinued Operations - Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets of discontinued operations	$ 0	$ 9,992
Current liabilities of discontinued operations	$ 0	13,496
Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents		2,780
Accounts receivable, net		2,055
Inventories		532
Deferred implementation costs		2,730
Related party receivables, net		206
Prepaid expenses and other current assets		1,689
Current assets of discontinued operations		9,992
Property, plant, and equipment, net		9,010
Deferred implementation costs, net of current		4,709
Goodwill		16,444
Intangible assets, net		40,314
Other assets		206
Total assets of discontinued operations		80,675
Accounts payable		681
Accrued and other current liabilities		5,199
Deferred revenue		7,616
Current liabilities of discontinued operations		13,496
Deferred revenue, net of current		6,111
Deferred income tax liabilities, net of current		838
Total liabilities of discontinued operations		$ 20,445

Discontinued Operations - Opera

Discontinued Operations - Operating Results of Discontinued Operations (Details) - Disposed of by Sale - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 1,498	$ 4,695	$ 7,619	$ 13,740
Cost of revenue	1,787	7,200	16,318	19,300
Selling, general and administrative	1,515	2,681	8,675	10,476
Research and development	(372)	3,895	7,571	12,352
Amortization of software license and acquisition-related assets	458	760	1,978	2,280
Other (income) expense	216	440	134	527
Loss from sale of Business	11,533	0	11,533	0
Gain from dissolution of a business component	(860)	0	(860)	0
Loss from discontinued operations, before income taxes	(12,779)	(10,281)	(37,730)	(31,195)
Provision for income taxes	6,604	201	7,008	850
Loss from discontinued operations, net of income taxes	$ (19,383)	$ (10,482)	$ (44,738)	$ (32,045)

Discontinued Operations - Signi

Discontinued Operations - Significant Cash Flow Items from Discontinued Operations (Details) - Disposed of by Sale - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization from discontinued operations			$ 8,829	$ 8,645
Loss from sale of Business	$ 11,533	$ 0	11,533	0
Proceeds from sale of Business			1,721	0
Capital expenditures			$ 4,668	$ 144

Business Combinations - Narrati

Business Combinations - Narrative (Details) - USD ($) $ in Thousands	Jan. 01, 2016	Dec. 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2017
Business Acquisition [Line Items]
Goodwill		$ 114,625				$ 114,625	$ 114,625
Measurement period adjustments				$ (697)	$ 1,635
NaviNet, Inc.
Business Acquisition [Line Items]
Percentage of voting interest acquired	100.00%
Cash paid in business acquisition	$ 83,529
Fair value of Series H units	52,500
Contingent arrangements or earnouts, maximum	12,250
Amount paid for working capital adjustment	455		$ 455
Escrow deposits received from working capital adjustment		$ 2,409
Goodwill	74,076
Assumed indebtedness repaid at closing of acquisition	$ 23,324
Measurement period adjustments				$ (697)	$ 1,361	300
Measurement period adjustment, increase (decrease) to goodwill related to a decrease in property and equipment						2,909
Measurement period adjustment, increase (decrease) to goodwill related to increase in R&D grant receivable						(697)
Measurement period adjustment, increase (decrease) to goodwill related to decrease in deferred revenue						(955)
Measurement period adjustment, increase (decrease) to goodwill related to a deferred tax liability increase						209
Measurement period adjustment, increase (decrease) to goodwill related to working capital increase						455
Measurement period adjustment, increase (decrease) to goodwill related to increase to accrued sales tax liability						188
Measurement period adjustment, increase (decrease) related to right to be reimbursed from seller for severance benefits						$ (2,409)
Term of agreement for severance benefits reimbursement		12 months
NaviNet, Inc. | Trade names
Business Acquisition [Line Items]
Estimated lives of definite-lived intangible assets	4 years
NaviNet, Inc. | Customer relationships
Business Acquisition [Line Items]
Estimated lives of definite-lived intangible assets	15 years
NaviNet, Inc. | Developed technology
Business Acquisition [Line Items]
Estimated lives of definite-lived intangible assets	7 years
NaviNet, Inc. | Series H units
Business Acquisition [Line Items]
Number of shares issued in acquisition	15,513,726
Fair value of Series H units	$ 52,500

Business Combinations - Summary

Business Combinations - Summary of Purchase Consideration (Details) - NaviNet, Inc. - USD ($) $ in Thousands	Jan. 01, 2016	Jun. 30, 2016
Business Acquisition [Line Items]
Cash paid to 3BE at closing	$ 74,823
Cash paid to option holders after closing	2,580
Cash paid to escrow account	6,126
Working capital settlement payment	455	$ 455
Fair value of Series H units	52,500
Total consideration	$ 136,484

Business Combinations - Allocat

Business Combinations - Allocation of Total Consideration to Net Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Jan. 01, 2016
Business Acquisition [Line Items]
Goodwill	$ 114,625	$ 114,625
NaviNet, Inc.
Business Acquisition [Line Items]
Cash and restricted cash			$ 4,804
Accounts receivable, net			10,693
Property, plant and equipment			5,044
Other assets and liabilities, net			4,561
Accounts payable			(4,585)
Accrued and other current liabilities			(3,674)
Deferred revenue			(2,603)
Deferred tax liability			(15,508)
Assumed indebtedness			(23,324)
Goodwill			74,076
Total fair value of net assets acquired			136,484
NaviNet, Inc. | Trade names
Business Acquisition [Line Items]
Definite-lived intangible assets			3,000
NaviNet, Inc. | Developed technology
Business Acquisition [Line Items]
Definite-lived intangible assets			32,000
NaviNet, Inc. | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets			$ 52,000

Accounts Receivable, net (Detai

Accounts Receivable, net (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Receivables [Abstract]
Outstanding and unpaid invoices excluded from accounts receivable and deferred revenue	$ 5,676	$ 1,900
Allowance for doubtful accounts	$ 148	$ 70

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 974	$ 1,308
Raw materials	0	377
Inventories	$ 974	$ 1,685

Prepaid Expenses and Other Cu54

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Other Current Assets And Other Current Liabilities [Abstract]
Prepaid expenses	$ 3,734	$ 3,083
Restricted cash	350	100
Other current assets	140	173
Prepaid expenses and other current assets	$ 4,224	$ 3,356

Prepaid Expenses and Other Cu55

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Other Current Assets And Other Current Liabilities [Abstract]
Payroll and related costs	$ 8,109	$ 9,821
NaviNet acquisition accrued earnout (See Note 4)	4,736	2,675
Other accrued and other current liabilities	7,123	7,536
Accrued and other current liabilities	$ 19,968	$ 20,032

Property, Plant and Equipment56

Property, Plant and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 38,681		$ 38,681		$ 31,942
Less: accumulated depreciation and amortization	(18,697)		(18,697)		(11,813)
Property, plant, and equipment, net	19,984		19,984		20,129
Depreciation expense	3,197	$ 1,995	9,793	$ 5,664
Amount capitalized to internal use software	976	4,018	5,482	6,271
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	13,956		13,956		13,391
Furniture and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,198		3,198		3,169
Leasehold and building improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	4,230		4,230		3,921
Internal use software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	15,853		15,853		10,371
Depreciation expense	1,546	$ 410	4,402	$ 686
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,444		$ 1,444		$ 1,090

Intangible Assets, net - Schedu

Intangible Assets, net - Schedule of Definite-Lived Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 116,530	$ 116,530
Less: accumulated amortization	(44,909)	(37,718)
Intangible assets, net	71,621	78,812
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	52,400	52,400
Developed technologies
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	61,130	61,130
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,000	$ 3,000

Intangible Assets, net - Narrat

Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 3,656	$ 5,520	$ 13,495	$ 17,326
NaviNet, Inc.
Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible assets related to acquisition				$ 87,000
NaviNet, Inc. | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated lives of definite-lived intangible assets			4 years
NaviNet, Inc. | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated lives of definite-lived intangible assets			15 years

Intangible Assets, net - Sche59

Intangible Assets, net - Schedule of Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2017	$ 2,197
2,018	8,788
2,019	8,788
2,020	8,038
2,021	8,038
Thereafter	35,772
Intangible assets, net	$ 71,621	$ 78,812

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Thousands	Jan. 01, 2016	Mar. 31, 2016	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2017
Goodwill [Line Items]
Goodwill				$ 114,625	$ 114,625
Goodwill associated with discontinued operations				16,444	$ 16,444
Measurement period adjustments		$ (697)	$ 1,635
NaviNet, Inc.
Goodwill [Line Items]
Goodwill	$ 74,076
Goodwill added during period	$ 74,076
Measurement period adjustments		$ (697)	1,361	$ 300
Healthcare Solutions (HCS)
Goodwill [Line Items]
Measurement period adjustments			$ 274

Investments - Narrative (Detail

Investments - Narrative (Details) $ in Thousands	Jun. 16, 2015USD ($)shares	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Sep. 30, 2017USD ($)director	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)shares
Schedule of Equity Method Investments [Line Items]
Income (loss) from related party equity method investment including impairment loss		$ (2,942)	$ (2,604)		$ (46,353)	$ (7,893)
NantOmics
Schedule of Equity Method Investments [Line Items]
Number of A-2 units purchased (in shares) | shares								169,074,539
Aggregate purchase price								$ 250,774
Ownership percentage		14.28%			14.28%
Difference between the carrying value and equity, intangible assets								28,195
Difference between the carrying value and equity, goodwill								$ 14,382
Other than temporary impairment on equity method investment				$ 35,991			$ 29,816
Income (loss) from related party equity method investment including impairment loss		$ (2,942)	$ (2,604)		$ (46,353)	$ (7,893)
Variable Interest Entity, Not Primary Beneficiary | IOBS
Schedule of Equity Method Investments [Line Items]
IOBS investment	$ 1,750
Number of shares acquired in IOBS | shares	1,750,000
Percentage of ownership in variable interest entity	35.00%
Number of directors NantHealth has right to elect | director					2
Number of directors on IOBS board | director					5

Investments - Summarized Financ

Investments - Summarized Financial Information (Details) - NantOmics - USD ($) $ in Thousands	6 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Sales		$ 5,294	$ 2,936
Gross loss		(4,330)	(3,113)
Loss from operations		(33,262)	(25,693)
Impairment on equity investments	$ (35,991)			$ (29,816)
Net loss		(41,420)	(21,841)
Net loss attributable to NantOmics		$ (39,088)	$ (20,273)

Convertible Notes - Narrative (

Convertible Notes - Narrative (Details)	Dec. 21, 2016USD ($)$ / shares	Sep. 30, 2017USD ($)Day	Dec. 31, 2016USD ($)	Dec. 15, 2016USD ($)
Debt Instrument [Line Items]
Number of consecutive trading days trading price evaluated		5 days
Remaining life of convertible notes		51 months
Convertible debt
Debt Instrument [Line Items]
Face value of debt	$ 107,000,000	$ 107,000,000	$ 107,000,000
Interest rate on debt	5.50%		5.50%
Proceeds from issuance of convertible notes, net of offering costs			$ 102,714,000
Initial purchasers' discount and debt issuance costs			4,286,000	$ 4,286,000
Conversion rate of convertible debt	82.3893
Conversion price of convertible debt (usd per share) | $ / shares	$ 12.14
Threshold of trading days | Day		20
Threshold consecutive trading days | Day		30
Threshold percentage of stock price trigger		120.00%
Business day period trading price evaluated		5 days
Threshold percentage of principal amount		98.00%
Discount rate		2.00%
Total liability component of convertible notes on date of issuance				83,079,000
Interest make-whole derivative on date of issuance				1,499,000
Carrying value of convertible notes on date of issuance		$ 81,634,000	$ 78,374,000	81,580,000
Conversion option reported in equity as additional paid-in capital				23,921,000
Purchasers' initial discount				972,000
Deferred financing offering costs				$ 3,314,000
Effective interest rate			12.82%
Convertible debt | Initial Purchasers Agreement
Debt Instrument [Line Items]
Face value of debt			$ 90,000,000
Proceeds from issuance of convertible notes, net of offering costs			92,797,000
Convertible debt | Cambridge Purchase Agreement
Debt Instrument [Line Items]
Face value of debt			10,000,000
Proceeds from issuance of convertible notes, net of offering costs			9,917,000
Convertible debt | Pursuant to the exercise of the overallotment by the Initial Purchasers
Debt Instrument [Line Items]
Face value of debt			$ 7,000,000

Convertible Notes - Summary of

Convertible Notes - Summary of Issuance of Convertible Debt (Details) - Convertible debt - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Dec. 15, 2016
Debt Instrument [Line Items]
Gross proceeds	$ 107,000	$ 107,000
Unamortized debt discounts and deferred financing offering costs	(25,366)	(28,626)
Net carrying amount	81,634	78,374	$ 81,580
Related party
Debt Instrument [Line Items]
Gross proceeds	10,000	10,000
Unamortized debt discounts and deferred financing offering costs	(2,153)	(2,436)
Net carrying amount	7,847	7,564
Others
Debt Instrument [Line Items]
Gross proceeds	97,000	97,000
Unamortized debt discounts and deferred financing offering costs	(23,213)	(26,190)
Net carrying amount	$ 73,787	$ 70,810

Convertible Notes - Interest Ex

Convertible Notes - Interest Expense Incurred (Details) - Convertible debt - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Debt Instrument [Line Items]
Accrued coupon interest expense	$ 1,471	$ 4,413
Amortization of debt discounts	991	2,883
Amortization of deferred financing offering costs	130	377
Total convertible notes interest expense	2,592	7,673
Related party
Debt Instrument [Line Items]
Accrued coupon interest expense	137	412
Amortization of debt discounts	94	275
Amortization of deferred financing offering costs	3	8
Total convertible notes interest expense	234	695
Others
Debt Instrument [Line Items]
Accrued coupon interest expense	1,334	4,001
Amortization of debt discounts	897	2,608
Amortization of deferred financing offering costs	127	369
Total convertible notes interest expense	$ 2,358	$ 6,978

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Assets
Cash equivalents	$ 64,279	$ 146,287
Liabilities
Interest make-whole derivative	26	271
Quoted price in active markets for identical assets (Level 1)
Assets
Cash equivalents	64,279	146,287
Liabilities
Interest make-whole derivative	0	0
Significant other observable inputs (Level 2)
Assets
Cash equivalents	0	0
Liabilities
Interest make-whole derivative	0	0
Significant unobservable inputs (Level 3)
Assets
Cash equivalents	0	0
Liabilities
Interest make-whole derivative	$ 26	$ 271

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 31, 2016	Sep. 30, 2017	Dec. 21, 2016
Derivative liability
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	2.00%
Convertible debt
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Face value of debt	$ 107,000,000	$ 107,000,000	$ 107,000,000
Period that must lapse prior to conversion for noteholder to receive interest make-whole payment	1 year
Discount rate		2.00%
Threshold period used to compute interest payment	3 years
Convertible debt | Related party
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Face value of debt	$ 10,000,000	$ 10,000,000

Fair Value Measurements - Chang

Fair Value Measurements - Changes in the Fair Value of Level 3 Liabilities (Details) - Derivative liability - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Interest make-whole derivative	$ 32	$ 271
Additions	0	0
Change in fair value	(6)	(245)
Interest make-whole derivative	26	26
Related party
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Interest make-whole derivative	3	25
Additions	0	0
Change in fair value	(1)	(23)
Interest make-whole derivative	2	2
Others
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Interest make-whole derivative	29	246
Additions	0	0
Change in fair value	(5)	(222)
Interest make-whole derivative	$ 24	$ 24

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Debt (Details) - Convertible debt - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 21, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face value	$ 107,000,000	$ 107,000,000	$ 107,000,000
Fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	76,394,000	118,572,000
Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	81,634,000	78,374,000
Related party
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face value	10,000,000	10,000,000
Related party | Fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	7,140,000	11,081,000
Related party | Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	7,847,000	7,564,000
Others
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face value	97,000,000	97,000,000
Others | Fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	69,254,000	107,491,000
Others | Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value	$ 73,787,000	$ 70,810,000

Commitments and Contingencies -

Commitments and Contingencies - Lease Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Operating Leased Assets [Line Items]
Rental expense charged to selling, general and administrative expense	$ 1,062	$ 1,111	$ 3,577	$ 3,351
Minimum
Operating Leased Assets [Line Items]
Remaining lives of operating leases			1 year		1 year
Maximum
Operating Leased Assets [Line Items]
Remaining lives of operating leases			5 years		5 years

Commitments and Contingencies71

Commitments and Contingencies - Related Party Promissory Note (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Jan. 04, 2016
Related Party Transaction [Line Items]
Related party promissory note	$ 112,666	$ 112,666
Affiliated Entity | Promissory Notes With NantCapital
Related Party Transaction [Line Items]
Related party promissory note	$ 122,675	$ 118,253	$ 112,666

Commitments and Contingencies72

Commitments and Contingencies - Indenture Obligations Under Convertible Notes (Details) - Convertible debt - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 21, 2016
Debt Instrument [Line Items]
Face value of debt	$ 107,000,000	$ 107,000,000	$ 107,000,000
Interest rate on debt		5.50%	5.50%

Commitments and Contingencies73

Commitments and Contingencies - Purchase Obligations Under License Agreements and Reseller Agreements (Details)	Aug. 25, 2017
NantHealth, Inc.'s Provider/Patient Engagement Solutions Business | Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Period minimum dollar bookings to be delivered	10 years

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes	$ 30	$ 55	$ 85	$ (19,203)
Effective tax rate	0.13%	0.21%	0.08%	17.25%
U.S. federal statutory rate	34.00%		34.00%

Stockholders_ Equity - Narrativ

Stockholders’ Equity - Narrative (Details)	Aug. 03, 2017shares	Aug. 09, 2016USD ($)shares	Jul. 25, 2016USD ($)shares	Jun. 09, 2016$ / sharesshares	Jun. 07, 2016USD ($)$ / sharesshares	Jun. 01, 2016USD ($)shares	Jan. 01, 2016USD ($)$ / sharesshares	Jun. 20, 2014USD ($)$ / sharesshares	Jan. 31, 2015USD ($)	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)
Class of Stock [Line Items]
Common stock, par value (usd per share) | $ / shares										$ 0.0001		$ 0.0001		$ 0.0001
Proceeds from initial public offering, net of offering costs												$ 0	$ 83,566,000
Amount of principal and interest under promissory note converted to shares												0	40,590,000
Tax payments related to stock issued												$ 2,740,000	5,822,000
Reverse stock split, conversion ratio						0.1818
Common stock authorized (shares) | shares										750,000,000		750,000,000		750,000,000
Preferred stock authorized (shares) | shares										20,000,000		20,000,000
Preferred stock, par value (usd per share) | $ / shares										$ 0.0001		$ 0.0001
Sequencing services agreement, amount paid by institution to the Company									$ 10,000,000
Deemed capital contribution from Chairman and CEO											$ 1,800,000	$ 0	3,420,000	$ 10,000,000
Other services										$ 1,996,000	2,623,000	5,504,000	9,309,000
Accretion to redemption value											0	$ 0	4,958,000		$ 16,042,000
NaviNet, Inc.
Class of Stock [Line Items]
Fair value of units transferred in acquisition							$ 52,500,000
Series H units
Class of Stock [Line Items]
Conversion of members' interests (in shares) | shares						3,749,998
Series H units | NaviNet, Inc.
Class of Stock [Line Items]
Number of shares issued in acquisition | shares							15,513,726
Acquisition, purchase price, (usd per share) | $ / shares							$ 3.3841
Fair value of units transferred in acquisition							$ 52,500,000
Redeemable Series F Units
Class of Stock [Line Items]
Offering price per share (usd per share) | $ / shares								$ 2.7995
Conversion of members' interests (in shares) | shares						10,714,285
Number of units sold in private placement, units | shares								53,580,996
Aggregate amount received in private placement								$ 150,000,000
Percentage of outstanding shares of purchaser potentially required to be redeemed by seller								100.00%
Private placement, interest payable								7.00%
Common stock
Class of Stock [Line Items]
Conversion of members' interests (in shares) | shares						99,661,906
Common Stock and Additional-Paid-in-Capital
Class of Stock [Line Items]
Conversion of members' interests						$ 525,388,000
Reseller agreement
Class of Stock [Line Items]
Other services											$ 1,080,000		$ 2,052,000
Equity Method Investee | Promissory Notes With NantOmics
Class of Stock [Line Items]
Amount of principal and interest under promissory note converted to shares						$ 40,590,000
Number of shares related party promissory note converted | shares						2,899,297
IPO
Class of Stock [Line Items]
Issuance of membership interests, shares | shares					6,500,000
Offering price per share (usd per share) | $ / shares					$ 14
Proceeds from initial public offering, net of offering costs					$ 83,566,000
Offering costs for initial public offering					$ 13,034,000
Over allotment option
Class of Stock [Line Items]
Issuance of membership interests, shares | shares				400,000
Offering price per share (usd per share) | $ / shares				$ 14
Unvested phantom units
Class of Stock [Line Items]
Shares of common stock issued for vested phantom units | shares			1,056,689
Shares withheld to satisfy tax withholding obligations | shares			538,794
Tax payments related to stock issued			$ 5,738,000
Unvested restricted stock
Class of Stock [Line Items]
Conversion of members' interests (in shares) | shares						10,462
Phantom Unit Plan Outside United States | Unvested phantom units
Class of Stock [Line Items]
Shares of common stock issued for vested phantom units | shares		16,818								2		59,276
Amount of cash paid to settle vested phantom units		$ 235,000								$ 0		$ 300,000
Disposed of by Sale | NantHealth, Inc.'s Provider/Patient Engagement Solutions Business
Class of Stock [Line Items]
Shares received for sale of provider/patient engagement solutions business (shares) | shares	15,000,000
Common stock, par value (usd per share) | $ / shares										$ 0.0001		$ 0.0001

Stockholders_ Equity - Units Co

Stockholders’ Equity - Units Converted to Shares (Details)	Jun. 01, 2016shares
Capital Unit [Line Items]
Number of member units converted to common shares, units	556,741,897
Former Series A Unit Holders
Capital Unit [Line Items]
Number of member units converted to common shares, units	420,255,676
Former Series B Unit Holders
Capital Unit [Line Items]
Number of member units converted to common shares, units	19,109,603
Former Series C Unit Holders
Capital Unit [Line Items]
Number of member units converted to common shares, units	3,470,254
Former Series D Unit Holders
Capital Unit [Line Items]
Number of member units converted to common shares, units	3,572,066
Former Series E Unit Holders
Capital Unit [Line Items]
Number of member units converted to common shares, units	35,720,664
Former Series G Unit Holders
Capital Unit [Line Items]
Number of member units converted to common shares, units	59,099,908
Former Series H Unit Holders
Capital Unit [Line Items]
Number of member units converted to common shares, units	15,513,726

Stockholders_ Equity - Schedule

Stockholders’ Equity - Schedule of Redeemable Series F Units (Details) - USD ($) $ in Thousands	Jun. 20, 2016	Jun. 01, 2016	Jun. 20, 2016	May 31, 2016	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2015
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion to redemption value					$ 0		$ 0	$ 4,958	$ 16,042
Expiration of Put Right at June 20, 2016							$ 0	171,000
Redeemable Series F Units
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, Redeemable Series F units and common stock			$ 170,417	$ 168,667		$ 166,042		$ 166,042
Accretion to redemption value				$ 1,750		2,625
LLC Conversion		$ (170,417)
Ending balance, Redeemable Series F units and common stock		170,417				$ 168,667			$ 166,042
Redeemable Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, Redeemable Series F units and common stock			170,417
Accretion to redemption value			583
LLC Conversion		170,417
Expiration of Put Right at June 20, 2016	$ (171,000)
Ending balance, Redeemable Series F units and common stock	171,000	170,417	171,000
Common Stock and Additional-Paid-in-Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
LLC Conversion		$ 525,388
Expiration of Put Right at June 20, 2016	171,000
Ending balance, Redeemable Series F units and common stock	$ 171,000		$ 171,000

Stock Based Compensation - Comp

Stock Based Compensation - Components of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	$ (4,962)	$ 5,194	$ (4,076)	$ 48,982
Amount capitalized to internal-use software and deferred implementation costs	(68)	1,594	661	1,594
Total stock-based compensation cost	(5,030)	6,788	(3,415)	50,576
Series C / Restricted Stock | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	34	45	80	(225)
Phantom units
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	(4,998)	5,149	(4,109)	49,207
Phantom units | Discontinued operations
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	(4,792)	1,618	(3,591)	8,527
Phantom units | Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	(239)	(122)	247	4,613
Phantom units | Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	(11)	2,433	(655)	24,288
Phantom units | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	44	1,220	(110)	11,779
Stock options | Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	$ 2	$ 0	$ (47)	$ 0

Stock Based Compensation - Narr

Stock Based Compensation - Narrative (Details)

Aug. 09, 2016USD ($)shares

Jul. 25, 2016USD ($)shares

Jun. 01, 2016shares

Sep. 30, 2017USD ($)shares

Sep. 30, 2016shares

Jun. 30, 2017shares

Sep. 30, 2017USD ($)shares

Sep. 30, 2016USD ($)shares

Dec. 31, 2016$ / sharesshares

Dec. 31, 2015shares

Mar. 31, 2015shares

Dec. 03, 2013shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Reverse stock split, conversion ratio

0.1818

Tax payments related to stock issued | $

$ 2,740,000

$ 5,822,000

Stock compensation plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares as a result of conversion of units (in shares)

28,973

Unvested restricted stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares as a result of conversion of units (in shares)

10,462

Number of restricted stock units unvested (in shares)

6,976

6,976

6,976

Unvested phantom units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Units granted to employees of related companies for providing services

995,364

995,364

Stock-based compensation expense expected to be recognized | $

$ 6,547,000

$ 6,547,000

Period for recognition of compensation cost not yet recognized

1 year 7 months

Shares of common stock issued for vested phantom units

1,056,689

Shares withheld to satisfy tax withholding obligations

538,794

Tax payments related to stock issued | $

$ 5,738,000

Number of restricted stock units vested and converted to common stock (in shares)

21,651

1,153,593

Number of restricted stock units unvested (in shares)

1,651,090

2,589,809

1,651,090

4,322,080

Unvested phantom units | Employee

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense expected to be recognized | $

$ 5,853,000

$ 5,853,000

Period for recognition of compensation cost not yet recognized

1 year 6 months

Unvested phantom units | Nonemployee

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense expected to be recognized | $

694,000

$ 694,000

Period for recognition of compensation cost not yet recognized

1 year 8 months

Series C units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Units outstanding (in shares)

3,470,254

3,470,254

Series C units | Unvested restricted stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense expected to be recognized | $

$ 145,000

$ 145,000

Period for recognition of compensation cost not yet recognized

1 year 1 month

Profits Interests Plan | Series C units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate units authorized for issuance (in shares)

63,750,000

Phantom Unit Plan | Unvested phantom units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate units authorized for issuance (in shares)

11,590,909

Number of shares available for grant

1,651,090

1,651,090

Phantom Unit Plan in United States | Unvested phantom units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock issued for vested phantom units

9,906

713,269

Shares withheld to satisfy tax withholding obligations

6,796

397,752

Tax payments related to stock issued | $

$ 29,000

$ 2,739,000

Phantom Unit Plan Outside United States | Unvested phantom units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of common stock issued for vested phantom units

16,818

2

59,276

Amount of cash paid to settle vested phantom units | $

$ 235,000

$ 0

$ 300,000

The 2016 Equity Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate units authorized for issuance (in shares)

6,000,000

6,000,000

The 2016 Equity Incentive Plan | Unvested restricted stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares as a result of conversion of units (in shares)

10,462

The 2016 Equity Incentive Plan | Series C units | Unvested restricted stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of restricted stock units vested and converted to common stock (in shares)

3,486

Number of restricted stock units unvested (in shares)

6,976

6,976

6,976

Board Of Director | The 2016 Equity Incentive Plan | Stock options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Period for recognition of compensation cost not yet recognized

2 years 7 months 24 days

Number of stock options issued (in shares)

500,000

Exercise price for stock options issued (usd per share) | $ / shares

$ 14

Unrecognized stock based compensation expense related to stock options | $

$ 21,000

$ 21,000

Stock Based Compensation - Acti

Stock Based Compensation - Activity of Phantom Units (Details) - Unvested phantom units - $ / shares	3 Months Ended	6 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Number of Units
Unvested phantom units outstanding, beginning balance (units)	2,589,809	4,322,080
Granted (in units)	0	113,656
Vested (in units)	(21,651)	(1,153,593)
Forfeited (in units)	(917,068)	(692,334)
Unvested phantom units outstanding, ending balance (units)	1,651,090	2,589,809
Weighted Average Grant date value per phantom unit
Unvested phantom units outstanding, beginning balance (usd per unit)	$ 14.66	$ 14.95
Granted (usd per unit)	0	4.75
Vested (usd per unit)	15.86	14.57
Forfeited (usd per unit)	14.84	14.79
Unvested phantom units outstanding, ending balance (usd per unit)	$ 14.56	$ 14.66

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 1,340	$ 362	$ 1,340	$ 2,298
Restructuring noncash charges			$ 1,549

Restructuring - Restructuring A

Restructuring - Restructuring Accrual Activity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Restructuring Reserve [Roll Forward]
Balance as of December 31, 2016			$ 0
Expenses, Net	$ 1,340	$ 362	1,340	$ 2,298
Cash			(1,028)
Balance as of September 30, 2017	$ 312		$ 312

Net Income (Loss) Per Share - R

Net Income (Loss) Per Share - Reconciliations of the Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended			12 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016		Dec. 31, 2015
Net income (loss) per share numerator:
Net loss from continuing operations		$ (23,015)	$ (26,392)	$ (108,839)	$ (92,106)
Net loss from discontinued operations		(19,383)	(10,482)	(44,738)	(32,045)
Net loss		(42,398)	(36,874)	(153,577)	(124,151)
Accretion to redemption value of series F/redeemable common stock		0	0	0	(4,958)
Accretion to redemption value of Series F units / redeemable common stock			0	0	4,958		$ 16,042
Net income (loss) for basic and diluted net income (loss) per share		$ (42,398)	$ (36,874)	$ (153,577)	$ (129,109)
Common Stock
Net income (loss) per share denominator:
Weighted-average shares for basic net loss per share (shares)		115,924,122	121,245,440	119,745,231	108,359,973
Effect of dilutive securities (shares)		0	0	0	0
Weighted-average shares for dilutive net income (loss) per share (shares)		115,924,122	121,245,440	119,745,231	108,359,973
Basic and diluted net loss per share from continuing operations (usd per share)	[1]	$ (0.20)	$ (0.22)	$ (0.91)	$ (0.90)
Basic and diluted net loss per share from discontinued operations (usd per share)	[1]	(0.17)	(0.08)	(0.37)	(0.29)
Basic and diluted total net loss per share (usd per share)	[1]	$ (0.37)	$ (0.30)	$ (1.28)	$ (1.19)
Redeemable Common Stock
Net income (loss) per share denominator:
Weighted-average shares for basic net loss per share (shares)			0		6,686,653
Effect of dilutive securities (shares)			0		0
Weighted-average shares for dilutive net income (loss) per share (shares)			0		6,686,653
Basic and diluted net loss per share from continuing operations (usd per share)			$ 0
Basic and diluted net loss per share from discontinued operations (usd per share)			0
Basic and diluted total net loss per share (usd per share)			$ 0		$ 0.74	[1]
[1]	The net income (loss) per share and weighted average shares outstanding for the nine months ended September 30, 2016, have been computed to give effect to the LLC Conversion (See Note 16) that occurred on June 1, 2016, prior to the Company’s initial public offering ("IPO"). In conjunction with the LLC Conversion, (a) all of the Company’s outstanding units automatically converted into shares of common stock, based on the relative rights of the Company's pre-IPO equityholders as set forth in the Company's limited liability company agreement and (b) the Company adopted and filed a certificate of incorporation with the Secretary of State of the state of Delaware and adopted bylaws. The Company adopted and filed an amendment to its certificate of incorporation with the Secretary of State of the state of Delaware to effect a 1-for-5.5 reverse stock split of its common stock on June 1, 2016.The net loss per share for the common stock for the nine months ended September 30, 2016 reflects $4,958 in accretion value allocated to the redeemable common stock. The redeemable common stock contained a put right, which expired unexercised on June 20, 2016. As a result of and as of that date, the shares were no longer redeemable and were included in common stock. See Note 19 for the calculation of net loss per share for common stock and redeemable common stock for the nine months ended September 30, 2016.

Net Income (Loss) Per Share - N

Net Income (Loss) Per Share - Narrative (Details)	Jun. 01, 2016
Earnings Per Share [Abstract]
Reverse stock split, conversion ratio	0.1818

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	6,976	10,462
Unvested phantom units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	1,651,090	4,561,255
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	500,000	0
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	8,815,655	0

Related Party Transactions (Det

Related Party Transactions (Details)	Jun. 01, 2016USD ($)shares	Mar. 08, 2016USD ($)	Jan. 22, 2016USD ($)	Jan. 04, 2016USD ($)$ / shares	Jun. 19, 2015USD ($)termtest	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 21, 2016USD ($)	Dec. 15, 2016USD ($)
Related Party Transaction [Line Items]
Related party receivables						$ 2,298,000		$ 2,298,000		$ 2,664,000
Related party payables, net of receivables balances including related party liabilities						15,513,000		15,513,000		13,694,000
Direct costs recorded as cost of revenue						11,472,000	$ 10,036,000	32,643,000	$ 33,214,000
Related party promissory note						112,666,000		112,666,000		112,666,000
Amount of principal and interest under promissory note converted to shares								0	40,590,000
Convertible debt
Related Party Transaction [Line Items]
Face value of debt						107,000,000		107,000,000		107,000,000	$ 107,000,000
Reseller agreement
Related Party Transaction [Line Items]
Term of agreement with related party					5 years 6 months
Affiliated Entity | Receivable from Ziosoft KK related to sale of Qi Imaging
Related Party Transaction [Line Items]
Related party receivables						2,082,000		2,082,000		2,126,000
Affiliated Entity | Cambridge Purchase Agreement | Convertible debt
Related Party Transaction [Line Items]
Face value of debt												$ 10,000,000
Accrued and unpaid interest on convertible notes						162,000		162,000		15,000
Affiliated Entity | Promissory Notes With NantCapital
Related Party Transaction [Line Items]
Accrued and unpaid interest on convertible notes						10,009,000		10,009,000		5,587,000
Interest bearing on related promissory note				5.00%
Per share price of stock shares to repay debt (usd per share) | $ / shares				$ 18.6126
Per share price of shares to settle debt (usd per share) | $ / shares				$ 1.484
Related party promissory note				$ 112,666,000		122,675,000		122,675,000		118,253,000
Equity Method Investee | Reseller agreement
Related Party Transaction [Line Items]
Number of renewals | term					3
Renewal term					3 years
Number of tests to qualify for first renewal option | test					300,000
Number of tests to qualify for second renewal option | test					570,000
Number of tests to qualify for third renewal option | test					760,000
Renewal option if threshold unmet, nonexclusive, number of years					3 years
Annual minimum fees, tier one					$ 2,000,000
Annual minimum fees, tier two					25,000,000
Annual minimum fees, tier three					$ 50,000,000
Related party payables						1,083,000		1,083,000		$ 1,950,000
Direct costs recorded as cost of revenue						1,549,000	1,651,000	3,937,000	2,982,000
Equity Method Investee | Promissory Notes With NantOmics
Related Party Transaction [Line Items]
Interest bearing on related promissory note			5.00%
Related party promissory note			$ 20,000,000
Additional advance on related party promissory note		$ 20,000,000
Amount of principal and interest under promissory note converted to shares	$ 40,590,000
Number of shares related party promissory note converted | shares	2,899,297
NantWorks | Affiliated Entity | Shared services agreement
Related Party Transaction [Line Items]
Net selling, general, and administrative service expenses incurred related to services provided by related parties						961,000	2,106,000	4,026,000	7,692,000
NantWorks | Affiliated Entity | Research and development services
Related Party Transaction [Line Items]
Net expenses incurred related to services provided by related parties						$ 0	$ 204,000	$ 239,000	$ 414,000